
Alzheimer's disease (AD) is one of the most common, severe neurodegenerative brain disorder characterized by the accumulation of amyloid-beta plaques, neurofibrillary tangles in the brain causing neural disintegration, synaptic dysfunction, and neuronal death leading to dementia. Although many US-FDA-approved drugs like Donepezil, Rivastigmine, Galantamine are available in the market, their consumption reduces only the symptoms of the disease but fails in potency to cure the disease. This disease affects many individuals with aging. Combating the disease tends to be very expensive. This review focuses on biochemical mechanisms in the neuron both at normal and AD state with relevance to the tau hypothesis, amyloid hypothesis, the risk factors influencing dementia, oxidative stress, and neuroinflammation altogether integrated with neurodegeneration. A brief survey is carried out on available biomarkers in the diagnosis of the disease, drugs used for the treatment, and the challenges in approaching therapeutic targets in inhibiting the disease pathologies. This review conjointly assesses the demerits with the inefficiency of drugs to reach targets, their side effects, and toxicity. Optimistically, this review directs on the advantageous strategies in using nanotechnology-based drug delivery systems to cross the blood-brain barrier for improving the efficacy of drugs combined with a novel neuronal stem cell therapy approach. Determinately, this review aims at the natural, non-therapeutic healing impact of physical exercise on different model organisms and the effect of safe neuromodulation treatments using repetitive Transcranial Magnetic Stimulation (rTMS), transcranial Electrical Stimulation (tES) in humans to control the disease pathologies prominent in enhancing the synaptic function.
Citation: Kiran Kumar Siddappaji, Shubha Gopal. Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches[J]. AIMS Neuroscience, 2021, 8(3): 357-389. doi: 10.3934/Neuroscience.2021020
[1] | Yangyang Yu, Yuan Liu, Shi Zhao, Daihai He . A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Mathematical Biosciences and Engineering, 2022, 19(10): 10361-10373. doi: 10.3934/mbe.2022485 |
[2] | Somayeh Fouladi, Mohammad Kohandel, Brydon Eastman . A comparison and calibration of integer and fractional-order models of COVID-19 with stratified public response. Mathematical Biosciences and Engineering, 2022, 19(12): 12792-12813. doi: 10.3934/mbe.2022597 |
[3] | Xinmiao Rong, Liu Yang, Huidi Chu, Meng Fan . Effect of delay in diagnosis on transmission of COVID-19. Mathematical Biosciences and Engineering, 2020, 17(3): 2725-2740. doi: 10.3934/mbe.2020149 |
[4] | Chentong Li, Jinhu Xu, Jiawei Liu, Yicang Zhou . The within-host viral kinetics of SARS-CoV-2. Mathematical Biosciences and Engineering, 2020, 17(4): 2853-2861. doi: 10.3934/mbe.2020159 |
[5] | Yuto Omae, Yohei Kakimoto, Makoto Sasaki, Jun Toyotani, Kazuyuki Hara, Yasuhiro Gon, Hirotaka Takahashi . SIRVVD model-based verification of the effect of first and second doses of COVID-19/SARS-CoV-2 vaccination in Japan. Mathematical Biosciences and Engineering, 2022, 19(1): 1026-1040. doi: 10.3934/mbe.2022047 |
[6] | David Moreno Martos, Benjamin J. Parcell, Raluca Eftimie . Modelling the transmission of infectious diseases inside hospital bays: implications for COVID-19. Mathematical Biosciences and Engineering, 2020, 17(6): 8084-8104. doi: 10.3934/mbe.2020410 |
[7] | Fang Wang, Lianying Cao, Xiaoji Song . Mathematical modeling of mutated COVID-19 transmission with quarantine, isolation and vaccination. Mathematical Biosciences and Engineering, 2022, 19(8): 8035-8056. doi: 10.3934/mbe.2022376 |
[8] | Fulian Yin, Jiahui Lv, Xiaojian Zhang, Xinyu Xia, Jianhong Wu . COVID-19 information propagation dynamics in the Chinese Sina-microblog. Mathematical Biosciences and Engineering, 2020, 17(3): 2676-2692. doi: 10.3934/mbe.2020146 |
[9] | Wenhan Guo, Yixin Xie, Alan E Lopez-Hernandez, Shengjie Sun, Lin Li . Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2. Mathematical Biosciences and Engineering, 2021, 18(3): 2372-2383. doi: 10.3934/mbe.2021120 |
[10] | Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249 |
Alzheimer's disease (AD) is one of the most common, severe neurodegenerative brain disorder characterized by the accumulation of amyloid-beta plaques, neurofibrillary tangles in the brain causing neural disintegration, synaptic dysfunction, and neuronal death leading to dementia. Although many US-FDA-approved drugs like Donepezil, Rivastigmine, Galantamine are available in the market, their consumption reduces only the symptoms of the disease but fails in potency to cure the disease. This disease affects many individuals with aging. Combating the disease tends to be very expensive. This review focuses on biochemical mechanisms in the neuron both at normal and AD state with relevance to the tau hypothesis, amyloid hypothesis, the risk factors influencing dementia, oxidative stress, and neuroinflammation altogether integrated with neurodegeneration. A brief survey is carried out on available biomarkers in the diagnosis of the disease, drugs used for the treatment, and the challenges in approaching therapeutic targets in inhibiting the disease pathologies. This review conjointly assesses the demerits with the inefficiency of drugs to reach targets, their side effects, and toxicity. Optimistically, this review directs on the advantageous strategies in using nanotechnology-based drug delivery systems to cross the blood-brain barrier for improving the efficacy of drugs combined with a novel neuronal stem cell therapy approach. Determinately, this review aims at the natural, non-therapeutic healing impact of physical exercise on different model organisms and the effect of safe neuromodulation treatments using repetitive Transcranial Magnetic Stimulation (rTMS), transcranial Electrical Stimulation (tES) in humans to control the disease pathologies prominent in enhancing the synaptic function.
Alzheimer's disease;
Amyloid-beta;
Neurofibrillary Tangles;
Amyloid Precursor Protein;
soluble Amyloid Precursor Protein alpha;
Amyloid Precursor Protein Intra Cellular Domain;
N-Methyl-D-Aspartate Receptor;
α-Amino-3-hydroxy-5-Methyl-4-isoxazole Propionic acid Receptor;
nicotinic Acetylcholine Receptors;
muscarinic Acetylcholine Receptors;
soluble Amyloid Precursor Protein beta;
Reactive Oxygen Species;
Protein Kinase C;
Protein Kinase A;
Extracellular signal-Regulated Kinases2;
Cyclin-Dependent Kinases 5;
AcetylcholinEsterase;
Cerebro Spinal Fluid;
Positron Emission Tomography;
Blood-Brain Barrier;
Physical Exercise;
Dementia with Lewy Bodies;
FrontoTemporal Dementia;
Magnetic Resonance Imaging;
functional Magnetic Resonance Imaging;
repetitive Transcranial Magnetic Stimulation;
transcranial Electrical Stimulation;
transcranial Direct Current Stimulation;
transcranial Alternating Current Stimulation;
transcranial Random Noise Stimulation;
transcranial Pulsed Current Stimulation;
Mild Cognitive Impairment;
Dynamin-related protein-1;
Presenilin-1;
Presenilin-2;
Insulin Degrading Enzyme;
Parkinson's Disease;
Apolipoprotein-E;
Protein Kinase B;
Glycogen synthase kinase 3α/β;
Electron Transport Chain;
Insulin-like Growth Factor-1;
Interleukin-6;
Nitrous Oxide Synthase-2;
Nuclear Factor Kappa B;
Lipoprotein Receptor-related Protein-1;
Orexin-A;
Orexin-B;
G-Protein-Coupled Receptors;
Orexin Receptor-type-1;
Orexin Receptor-type-2;
Brain-Derived Neurotrophic Factor;
Obstructive Sleep Apnea (OSA);
Central Disorders of Hypersomnolence;
Rapid Eye Movement;
Electroencephalogram;
Traumatic Brain Injury;
123I-Meta-IodoBenzylGuanidine;
[11C]-Pittsburgh compound B;
Fluorine 18-labeled;
Montreal Cognitive Assessment;
Total tau;
phosphorylated-tau;
Visinin-Like Protein;
Neuro Filament Light Protein;
Heart Fatty Acid Binding Protein;
Neuron-Specific Enolase;
Chitinase-3-like protein-1;
Tumor Necrosis Factor Ligand Superfamily member-10;
Angiotensin-Converting Enzyme;
triple-transgenic-AD;
Voxel-Based Morphometry
The COVID-19 pandemic caused by the novel coronavirus (SARS-CoV-2) has received increased attention from both scientists and public health policymakers worldwide compared to previous epidemics such as the Spanish flu and MERS [1]. Indeed, since the first report of SARS-CoV-2 in late 2019, many governments have implemented stringent restrictions (both at the start of the pandemic and repeatedly throughout) to limit the spread of the virus. These include general measures such as the ban of mass gatherings, travel restrictions, lockdowns and curfews, but also individual level measures such as improved personal hygiene, social distancing, and face mask wearing [2,3,4,5,6,7]. A combination of the rapid propagation of SARS-CoV-2, the related symptoms, the resulting deaths, and the responses of public bodies across the world have inspired numerous studies into understanding the biology of the pathogen [8,9,10,11,12], the numerous COVID-19 epidemic outbreaks [13,14,15], and damages to health, social and economic activities among other aspects of human societies [16,17,18,19].
To inform and guide health policies, researchers use two general classes of models to understand the dynamics of epidemic outbreaks: phenomenological (regression) models and mechanistic (compartmental) models [20]. The use of compartmental mathematical models, which currently prevails for SARS-CoV-2 data [21], allows for the explicit structuring of a target population into epidemiological states relevant to the studied pathogen and its effects on exposed and infected patients. One major advantage of these compartmental models is the possibility to structure the target population based on the attitudes of individuals regarding measurements such as personal hygiene, social distancing, face mask-wearing, and vaccination. As a result, these models can be used to simultaneously model the dynamics of a pathogen's spread and the opinions and attitudes related to prophylactic measures [22,23,24,25,26,27,28,29,30,32,33,91]. Unfortunately, many of these models only incorporate vaccine opinions. However, the dynamics of opinion and attitudes regarding other measures and their impact on disease dynamics can substantively differ from the dynamics of vaccine opinions, mainly because these behaviors demand stronger engagement in the required frequency of opinion affirmation [34]. For instance, in the context of the COVID-19 epidemic, individuals needed to regularly wash their hands when the environment was full of potentially contaminated areas, wear face masks when traveling to any shared public space, and maintain the minimum social distance when interacting with others. In the context of insignificant variations of attitudes towards prophylactic measures, the use of approaches that disregard the dynamics of such attitudes when building disease models remains sound. However, significant shifts in attitudes toward prophylactic measures usually follow the outbreak of a disease [35,36,37,38], and a failure to account for the feedback of opinion/attitude dynamics on modeled disease dynamics reduces the reliability of findings and policies based on such models. In addition to these inherent changes in opinions, once a disease outbreaks, the wide accessibility of populations to mass media, in particular social media, can induce quite sharp variations in the distribution of opinions and attitudes because of a rapid spread of evidence, as well as fake pieces of information on the disease, the underlying pathogen, the related symptoms, the advocated barrier measures, and any available vaccines [39,40]. Therefore, integrating opinion dynamics in mathematical models for disease dynamics is a major point to consider when building models to inform public health policies.
Aside from the largely studied dynamics of the spread of SARS-CoV-2, many studies have reported on the adherence of exposed populations to prophylactic measures [41,42,43,44,45,46,47,48,49,50]. The potential or actual effects of the implementation of barrier measures on the dynamics of the spread of SARS-CoV-2 have also been investigated, to some extent [51, 52, 53, 54, 55, 56, 57, 58, 59]. In addition, many works have integrated attitudes toward vaccines in either mechanistic or network models describing COVID-19 dynamics [23,53,60,61,62,63,64,65]. However, so far, few studies have considered information on adherence to barrier measures into the mechanism describing the propagation of the pathogen within a population [52,55,66,67,68,69].
The SIR-Opinion model of Tyson et al. [34] is a simple disease-opinion dynamics model appropriate for joint modeling of COVID-19 dynamics and related prophylactic opinions over a short period. For sound modeling of COVID-19 data along with the levels of adherence to prophylactic measures, we extend the SIR-Opinion model to account for the partial detection of infected individuals. Indeed, only a small amount of SARS-CoV-2-infected individuals are generally identified and reported, mainly because of the prevalence of asymptomatic infectious [70,71,72]. For inference in the resulting SIQR-Opinion model, we consider the hybrid modeling technique introduced by Tovissode et al. [20], where the identified SARS-CoV-2 infected individuals are first modeled using a growth curve, and the result is added into the SIQR model framework to avoid identifiability issues when fitting the model. For illustrative purposes, we use the proposed model to (i) determine the best growth curve to adjust for the number of infected individuals infected and (ii) evaluate the effects of prophylactic attitudes on the dynamics (as measured by the reproduction number) of COVID-19 in West Africa.
In this study, we developed a two-stage estimation model. The first is an extension of a disease compartmental model. However, instead of estimating the infected individuals, I(t), with this compartmental model, we opted for a growth model.
Following Hethcote et al. [73], a susceptible–infectious–quarantined–removed (SIQR) model is used to model the COVID-19 dynamic in West Africa. The four compartments considered in this model are the susceptibles (S), the infectious but undetected individuals (I), the quarantines (Q), and the removed (R). The quarantine state Q stands for the detected active cases of SARS-CoV-2 infected individuals. We assumed neglected births, net migrations, and the natural mortality rates associated with each compartment, given the short period of each considered COVID-19 wave. At a given time t⩾0, the population size is given by:
N(t)=S(t)+I(t)+Q(t)+R(t). | (2.1) |
The SIQR model is described at time t by the following system of differential equations:
˙S(t)=−λ(t)S(t), | (2.2a) |
˙I(t)=λ(t)S(t)−αI(t)−δI(t), | (2.2b) |
˙Q(t)=δI(t)−γQ(t), | (2.2c) |
˙R(t)=αI(t)+γQ(t). | (2.2d) |
with the non-negative initial conditions, S(0) = S0, I(0) = I0, Q(0)=Q0, and R(0) = R0 where (S0,I0,Q0,R0)T∈[0,∞)4.
In System (2.2), α is a rate that measures the removal of non-detected infectives, δ is the rate of detecting new cases of infected people, γ stands for the removal of quarantined people, and the force of infection is λ(t)=βI(t)N(t)−Q(t), where β is the rate of contacts sufficient for SARS-CoV-2 transmission.
Tyson et al. [34] identified four levels of prophylactic behavior (use of the mask, physical distance, hand hygiene, coughing hygiene, and avoidance of touching the face) represented by the following spectrum of prophylactic attitudes/opinions:
O={−2,−1,1,2}. |
Since the infected do not really have an opinion and the removals are not heard since they have recovered from COVID-19, we considered just the opinion of the susceptible classes. From this spectrum, we have i cases among susceptible individuals, Si symbolizes the susceptible with attitude i for any opinion i∈O: S−2 represents individuals with the highest degree of prophylactic behavior (and thus the least susceptible to disease) and S2 corresponds to individuals with the lowest degree of prophylactic behavior (and thus the most susceptible to disease). Individuals in the middle of the spectrum, S−1 and S1, exhibit moderate levels of prophylactic behavior. At any time t, the identity S(t)=∑i∈OSi(t) represents the susceptible population. The exchange of information about the prevalence of the disease, as well as government control measures, can change an individual's opinion. It is to this end that Tyson et al.[34] insert the "impact" and "amplification" effects into their model, whereby attitudes/opinions are updated in response to either biased assimilation or confirmation bias caused by contact between susceptible individuals. The rates and directions of mutual opinion effects determine the dynamics of opinions in the susceptible population in this framework. They defined the "influence function" as the rate ωi at which a sensitive individual Si influences the rest of the susceptible population. Tyson et al. [34] incorporated linear and saturating impacts wi as functions of the proportion of the infectious population (I). In terms of influence directions, when an Si individual impacts an Sj individual, the affected individual's attitude is updated, and we have one of the two cases: opinion amplification with probability ϕ or no opinion amplification with probability 1−ϕ. Opinion amplification appears to express the tendency to become more confident in one's opinion after interacting with like-minded individuals. It should be noticed that in the sensitive population, changes in opinion are reflected by the rates χ(i,j)(t) of outgoing flows (opinion change i→j), which are defined as follows:
χ(2,1)(t)=ω−2(t)S−2(t)+ω−1(t)S−1(t)+(1−ϕ)ω1(t)S1(t)N(t)−Q(t), | (2.3a) |
χ(1,2)(t)=ϕω1(t)S1(t)+ω2(t)S2(t)N(t)−Q(t), | (2.3b) |
χ(1,−1)(t)=ω−2(t)S−2(t)+ω−1(t)S−1(t)N(t)−Q(t), | (2.3c) |
χ(−1,1)(t)=ω1(t)S1(t)+ω2(t)S2(t)N(t)−Q(t), | (2.3d) |
χ(−1,−2)(t)=ω−2(t)S−2(t)+ϕω−1(t)S−1(t)N(t)−Q(t), | (2.3e) |
χ(−2,−1)(t)=(1−ϕ)ω−1(t)S−1(t)+ω1(t)S1(t)+ω2(t)S2(t)N(t)−Q(t). | (2.3f) |
Since the prevalence of the disease drives a shift in the susceptible population, we assume that the influence functions, ωi=ωi(I), vary with the proportion of infected I in the population. To investigate a range of potential epidemic responses, [34] defined four plausible influence functions. As shown in Table 1, the functions considered are linear, saturating, fixed-order saturating, and reverse-order saturating ωi(I) functions. As ωi(I) changes during the epidemic, these functions serve to either increase or decrease the influence of each subpopulation Si. In Table 1, each function ωi(I) starts at the same point, ωi(0)≡0, and "I" comes from equation (2.8). The parameters in Table 1 are described in Table 2. The SIQR model is further detailed in Figure 2. The following system at time t describes the SIQR-Opinion dynamics model:
˙S2(t)=χ(1,2)S1(t)−(χ(2,1)+λ2)S2(t) | (2.4a) |
˙S1(t)=χ(2,1)S2(t)−(χ(1,2)+λ1)S1(t) | (2.4b) |
˙S−1(t)=χ(1,−1)S1(t)−(χ(−1,1)+λ−1)S−1(t) | (2.4c) |
˙S−2(t)=χ(−1,−2)S−1(t)−(χ(−2,−1)+λ−2)S−2(t) | (2.4d) |
˙I(t)=λ2S2(t)+λ1S1(t)+λ−1S−1(t)+λ−2S−2(t)−αI(t)−δI(t) | (2.4e) |
˙Q(t)=δI(t)−γ(t)Q(t) | (2.4f) |
˙R(t)=αI(t)+γ(t)Q(t) | (2.4g) |
ωi(I) | Linear | Saturating | Fixed-order saturating | Reverse-order saturating |
ω−2(I) | ω0(1+ωmaxI) | ω0(1+ωmaxI2k2+I2) | ω0(1+ωmaxIk+I) | ω0(1+12ωmaxIk+I) |
ω−1(I) | ω0(1+12ωmaxI) | ω0(1+12ωmaxIk+I) | ω0(1+12ωmaxIk+I) | ω0(1+ωmaxIk+I) |
ω1(I) | ω0(1−12I) | ω0(12+12I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) | ω0(I−1k−1+I−1) |
ω2(I) | ω0(1−I) | ω0(I−2k−2+I−2) | ω0(I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) |
Source: Tyson et al. [34]. Ecological functional responses give the lead-up to the linear and saturating influence functions. A modification to the saturating function, called the fixed-order saturating function, prevents the influence functions' ordering from changing for low levels of infection. When some preventive behaviors are judged as socially unacceptable, and an inversion of the influence ordering is possible, the reverse-order saturating influence function is used. |
Parameter | Description | Values | Unit | Source |
a | Factor discounting of the infection rate | estimated | ||
α | Removal rate of non detected infectives | 1/10 | - | Assumed |
ϕ | Baseline probability of opinion amplification | estimated | - | |
w0 | Baseline influence rate (when disease is not perceived) | 0.1 | percentage−1 | Tyson et al. [34] |
w∞ | Skewness parameter of influence functions | estimated | - | |
k | Half-influence saturation constant | estimated | day−1 | |
δ | Rate of detecting new cases of infected people | 0.009 | Honfo et al. [79] | |
β0 | Baseline transmission rate by I infectious | estimated | day−1 | |
βi | Transmission rate by infectious with opinion i | estimated | day−1 | |
γ | Removal rate of quarantined people | estimated | ||
K | carrying capacity or maximum cumulative case incidence | estimated | ind. | |
ν | growth acceleration parameter | estimated | ||
ω | the growth rate constant | estimated | day−1 | |
τ | constant of integration determined by the | estimated | ||
initial conditions of the epidemic. | day−1 |
with the non-negative initial conditions Si(0)=S0i,I(0)=I0, Q(0)=Q0, and R(0)=R0 where (I0,Q0,R0)⊤∈[0,∞)3, and S0i≥0 for i∈O.
In the system (2.4), we assume that a person's attitude affects their susceptibility to infection and the force of infection for Si individuals has the form
λi(t)=βiI(t)N(t)−Q(t), | (2.5) |
where, for i∈O, βi is the rate of contacts sufficient for transmission for a Si susceptible. For simplicity, the infection rate is modeled as a function of attitude using a single parameter a>1 [34]. We assume:
β2=β0,β1=1aβ0,β−1=1a2β0,β−2=1a3β0, | (2.6) |
where β0 represents the baseline infection rate, and each increase in prophylactic behavior results in a factor a discounting of the infection rate. In the system (2.4), the dots represent partial derivatives with respect to time (t), and the constant rate parameters of the model are described in Table 2. We allow the removal rate of quarantined people γt from Qt to be time-variable, as previously performed in [20] do, and it takes the logistic form.
γt=[1+e−(κ0+κt)]−1. | (2.7) |
This is reasonable when the reported positive cases per unit of time are supplemented by removals. To avoid identifiability problems, we followed the approach described by Tovissode et al. [20] to determine the infected.
The growth curve that is fitted to the SARS-CoV-2 infected individuals in West Africa is developed in this section. Following Tovissode et al.[74], the number of infected persons in a target population has the following form:
I(t)=δ−1˙C(t), | (2.8) |
where
˙C(t)=dC(t)dt, | (2.9) |
is the number of cases detected at time t (i.e., the number of infected, detected, and isolated cases) and δ∈(0,1] is the detection rate assuming constant during the epidemic. In (2.9), C(t) represents the cumulative SARS-CoV-2 infected individuals and then the growth curve to be fitted. The generalized logistic model (GLM), also known as Richards' model, can improve the fit of SARS-CoV-2 data well since, for real-time outbreak prediction, this empirical function has made major marvellous coincidences with real SARS, Zika, and Ebola epidemic data [75,76,77]. Based on population biology, this model assumes an initial exponential growth phase that saturates as the number of cases increases due to ongoing control efforts and newly acquired human behaviors.
At time t, the dynamics of C can be represented as:
C(t)=K((1+e−ut)−1ν), | (2.10) |
with ut=νω(t−τ), K>0 is the carrying capacity or maximum cumulative case incidence, ν>0 is a growth acceleration parameter, ω>0, the growth rate constant, and τ is a constant of integration determined by the initial conditions of the epidemic (see Tovissode et al. [20] for more information). The expression of the growth curves ˙C(t) and ¨C(t) can be found in Table A1 within the appendix.
We calculated the fundamental reproduction number, R0, to determine how the COVID-19 epidemic is impacted by introducing an opinion dynamic. The basic reproduction number is the expected number of secondary cases resulting from a single susceptible individual's infection. To calculate the control reproduction number of the model, we followed the Diekmann et al.[78] next-generation's approach.
At the start of the epidemic, we have S0=N0−1,I0=1,Q0=0,R0=0. The disease-free equilibrium point of the model is given by (S0,0,0,0).
At the infection-free steady state, I=R=0, hence S=N−Q.
˙I(t)=β2I(t)+β1I(t)+β−1I(t)+β−2I(t)−(α+δ)I(t), | (2.11a) |
˙Q(t)=δI(t)−γ(t)Q(t). | (2.11b) |
Let M be the next generation matrix (NGM) for all new infections and T+Σ be the jacobian of the infection subsystem (2.11). The matrix transmissions T, the transitions matrix Σ, and the NGM M are the following:
T=(β2+β1+β−1+β−2000),Σ=(α+δ0δ−γt).M=−TΣ−1=(β2+β1+β−1+β−2000)×(1α+δ0−δγt+(α+δ)−1γt)M=(β2+β1+β−1+β−2α+δ000). |
The dominant eigenvalue of M is
R0=β2+β1+β−1+β−2α+δ, | (2.12) |
R0=β0a3(α+δ)+β0a2(α+δ)+β0a(α+δ)+β0(α+δ). | (2.13) |
The number of people in a population who can contract an infection from a single person at any one time is often referred to R. By multiplying the basic reproduction number by the proportion of the host population that is susceptible, one can get the effective reproduction number (R). Thus we have
Rt=∑i∈OSi(t)N(t)−Q(t)R(i)0; |
Thus
Rt=∑i∈OβiSi(t)(α+δ)(N(t)−Q(t)). |
The parameters of the system (2.3) are assumed to be known and constant, and they are derived from the literature [34] (Table 2). As for those of equation (2.4), some are assumed to be known and are extracted from [20] and [79]. To obtain the recovery rate γt, the logistic regression parameters in equation (2.15) are adjusted on the new removal Rt. Knowing the new infected case Yt and the active case Qt−1, logistic regression models with probability mass functions (pmf) are used to model the number of new removals (Rt):
fG(Rt∣θ,Qt−1,Yt)=(Qt−1+YtRt)γRtt(1−γt)Qt−1+Yt−Rt, | (2.14) |
where
γt=[1+eκ0+κt]−1, | (2.15) |
with θ=(K,ω,ν,τ,σ,κ0,κ)⊤. In equation (2.14), we considered the number of known active cases Q0=0 at t=0.
The maximum likelihood (ML) is used to estimate the parameters K,ω,ν, and τ in (2.10). To do this, each new confirmed infected case Y1,Y2,⋯,Yn is given an appropriate statistical distribution with an expectation of λt=˙Ct and a dispersion parameter σ>0 [74]. The inference under Poisson, negative binomial and log-normal distributions was discussed.
Poisson distribution: Since we are dealing with the counts' incidence, Yt can be assumed to follow the Poisson distribution, and we have Yt∼ Pois (˙Ct) with pmf
fY(Yt∣θ)=(λYttexp−λt)Yt!. | (2.16) |
The incidence case Yt has an expectation E[Yt]=λt and variance Var[Yt]=λt.
Negative binomial distribution: It can be assumed that Yt follows the negative binomial distribution as new confirmed cases are counts, and we have Yt∼NB(˙Ct,σ) with pmf
f(Yt∣θ)=Γ(Yt+1/σ)Γ(Yt+1)Γ(1/σ)(σλtσλt+1)1/σ(1σλt+1)Yt. | (2.17) |
The expectation E[Yt]=λt and variance Var[Yt]=λt(1+σλt) are then established for the new detected case Yt.
Log-normal distribution: Since zero incidence cases are common in epidemic data, the logarithmic function is often applied to the shifted cases (Yt+1), and we consider the log-normal distribution assumption, where Yt+1∼LN(Yt+1,σ) with pdf
fY(Yt∣θ)=1σ(Yt+1)√2πexp(−12[log(Yt+1)−log(λt+1)σ+σ2]2), | (2.18) |
the mean E[Yt]=λt and the variance Var[Yt]=(λt+1)2(eσ2−1).
Let's consider two components ,ℓY(θ) and ℓG(θ), representing the log-likelihood function for new infected case Yt and new removal Rt, respectively. The conditional maximum likelihood estimates ˆθ of θ can be produced using an optimization technique to maximize the log-likelihood function ℓ [20]:
ℓ(θ)=ℓY(θ)+ℓG(θ),where ℓY(θ)=n∑t=1logfY(Yt∣θ),ℓG(θ)=n∑t=1logfG(Rt∣θ,Qt−1,Yt). | (2.19) |
The maximum likelihood estimates of the components θY=(Ω,ω,ν,τ,σ)⊤ and θG=(κ0,κ)⊤ of the parameter vector θ=(θ⊤Y,θ⊤G′)⊤ can be produced by maximizing ℓY and ℓG, respectively. We consider the common deviance statistic used in generalized linear models to assess the goodness-of-fit of the binomial model associated with Rt and the log-normal models associated with Yt because both the binomial and the log-normal distributions are members of the exponential family [20]. The likelihood ratio statistic is considered while choosing the concise model that best fits the observed data.
The sixteen countries of Western Africa (Benin, Burkina Faso, Cape Verde, The Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, and Togo) had been considered for this study. Information about these countries are in Table B1. Based on the latest United Nations estimates (worldometers.info), this region has a current population of approximately 5.16% of the world's population and includes nine of the 25 poorest countries in the world. The first case of Covid-19 in West Africa was recorded at the end of February 2020 (oecd). Implementation of prophylactic measures against the spread of COVID-19 in most West African countries began in March (Table B1). We considered the beginning of the pandemic expansion in West Africa (February 28, 2020) as our starting date for our data. The final date considered is February 23, 2021, which represents the last date before vaccine implementation in West Africa (Ghana received 600,000 doses on February 24, 2021, and Ivory Cost received 504,000 doses two days later (unicef portal)).
We aggregated the data of newly detected cases, population, recoveries, and death by date. As of February 24, 2021, there were approximately 4.19E+08 humans, among which 397826 were detected cases, 44958145 were recoveries cases, and 5314 were deaths in West Africa (Table B2). The newly detected cases and population data were obtained from the OWID data portal [80]. As for the quarantine recovery data, it was taken [81]. This period corresponds approximately to the first and second waves of the COVID-19 pandemic in West Africa (fig 3).
We fitted the Bertalanffy-Richards growth curve to Y′t 's new daily infections based on Poisson, negative binomial and log-normal distributions for each wave. The R software's optim function was used to maximize the log-likelihood. Using likelihood ratio tests, we additionally fitted Bertalanffy-Richards. We used the Arkaike Information Criterion (AIC) and the R2 values based on the cumulative detected case to pick the best model. To obtain the recovery rate of quarantined people γt, we used the R procedure glm [82] with the family specification "family = binomial(logit)". We integrate the quadratic interaction in the logistic model. The parameters K,ω,ν,τ,σ in Table 2 are estimated using the R software.
A recent study on the adherence of the West African population to prophylactic measures [83] revealed that there are individuals who support but do not apply the prophylactic measures and those who support and fully adhere and apply them. This is consistent with the -2, -1 attitude levels defined by [34]. The opinion parameters β0 in Table 2 are estimated using Matlab R2021a. We exclude 1 of the population and set S0=0.01∗N0 because COVID-19 rarely affects children and people living in rural areas in the majority of African countries. We then set S0i=zi∗S0 with zi being the population's susceptible class proportion in 2.3. According to PERC(2022) [83], z1=66, z2=24 (z1+z2=90), z3=5, and z4=5 (equitable distribution of the remaining 10% between z3 and z4) for wave1 and z1=63, z2=25 (z1+z2=88), z3=7, and z4=7 (equitable distribution of the remaining 14% between z3 and z4) for wave 2. We used the Matlab function datasample to estimate the initial conditions of each of the model's state variables. On the first day of the pandemic's expansion, we assume there was only one active person. We then define Q0 to equal 1. The integrated ODE45 function of Matlab was used to obtain the solutions of (2). The parameters K,ω,ν,τ estimated in R are used to find the new detected parameters in (2). The target of the fitting included finding the optimal set of parameter values that minimizes the root mean square differences between the new daily detected COVID-19 cases observed in West Africa and the new daily detected COVID-19 cases predicted from our model. This was done using the nonlinear least squares method in Matlab R2021a, with the function "fminsearchbnd". Since minimization in a multivariate framework uses starting values, we used a cross-validation technique to ensure both the explanative and predictive power of the model. We ran 1000 simulations of starting values considering 90% and 10% for training and test datasets, respectively. Considering 50 simulations, the starting values related to the minimum RMSE (RMSE1) were used to compute the minimum RMSE for the test sets (RMSE2). We found 375.13 and 244.10 for RMSE1 and RMSE2, respectively, for the first wave and 428 and 509 for wave2. Additionally, we determined the estimated parameters' 95% confidence interval.
At this stage, we numerically analyzed the model to assess the effect of prophylactic behavior on the COVID-19 dynamic in West Africa. Therefore, using estimated parameters and the initial circumstances of the model, we calculated the values of the effective reproduction number Rt, and the basic reproduction number R0, and we simulated some scenarios on Rt in order to analyze the impact of opinions on the dynamic of COVID-19.
Table 3 indicates that the growth model involving Richard's growth curve under the assumption of the negative binomial distribution has the lowest AIC value for the cumulative COVID-19 case for the first wave and behaved well for the second wave. Therefore, we considered Richard's negative binomial distribution curve for the adjustment. From Figure C1 in the appendix, we observed that our model was well-fitted to the new and cumulative detected cases for West Africa. Figure C1c shows the probabilities of removals from actives (quarantined) and the fitted values based on the logistic regression models for removal probabilities. The logistic model doesn't fit the removals of COVID-19 in West Africa well for both waves. However, we have kept it since the adjustment of active cases is good (Figure C2d-C3d).
Wave | Selection criterion | Richards-Poisson | Richards-Nbinomial | Richards-Lognorm |
Wave1 | AIC | 17177.84 | 3105.51 | 3149.41 |
R2(Y) | 0.83 | 0.79 | 0.79 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Wave2 | AIC | 13268.57 | 1798.62 | 1794.54 |
R2(Y) | 0.82 | 0.82 | 0.82 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Tablenote: Akaike Information Criterion AIC; New infected detected Y; cumul as cumulative |
Results obtained with Richard's model (Table 4) indicate that the maximum case size is estimated at 206746 people (CI = [205800; 207700]) for wave 1 and 238299 people (CI = [236800; 239800]) for the wave 2. At the outbreak (t = 0), the probabilities of recovery are ^γ0 = 0.009 and ^γ0=0.147 for wave 1 and 2, respectively. In the first wave, an increase in the number of days is associated with an increase in the likelihood of belonging to the COVID-19 removal class (κ1=0.01), and in the second wave, a decrease in the likelihood of being removed from active case COVID-19 (κ1=−0.007).
(a) First wave | ||||||
Parameter | Estimate | Std.Error | z | P (>— z —) | CI | |
K | 206746 | 495.5 | 417.154 | < 0.001 | 205800 | 207700 |
ω | 0.093 | 0.002 | 46.500 | < 0.001 | 0.089 | 0.099 |
ν | 0.266 | 0.008 | 33.250 | < 0.001 | 0.2505 | 0.282 |
τ | 72.730 | 1.625 | 44.757 | < 0.001 | 69.550 | 75.920 |
κ0 | -4.612 | 0.026 | -177.21 | < 0.001 | -4.663 | -4.561 |
κ1 | 0.016 | 0.0003 | 45.390 | < 0.001 | 0.015 | 0.017 |
κ2 | -4.2E-05 | 1.125E-06 | -37.45 | < 0.001 | -4.434E-05 | -3.993E-05 |
(b) Second wave | ||||||
Estimate | Std.Error | z | P (>— z —) | CI | ||
K | 238299 | 771.3 | 308.959 | < 0.001 | 236800 | 239800 |
ω | 0.027 | 0.0002 | 135 | < 0.001 | 0.027 | 0.027 |
ν | 3.05 | 0.066 | 46.212 | < 0.001 | 2.923 | 3.183 |
τ | 350.4 | 0.207 | 1692.754 | < 0.001 | 350 | 350.8 |
κ0 | -1.913 | 0.227 | -8.416 | < 0.001 | -2.358 | -1.467 |
κ1 | -0.007 | 0.002 | -4.917 | < 0.001 | -0.010 | -0.004 |
κ2 | 1.26E-05 | 2.404E-06 | 5.238 | < 0.001 | 7.878E-06 | 1.730E-05 |
Table notes: ind. is individuals, K>0 is the ultimate pandemic size (detected) or maximum cumulative case incidence, ν>0 is a growth acceleration parameter, ω>0( day −1) is the "intrinsic" growth rate constant and τ is a constant of integration determined by the initial conditions of the epidemic, κ0 and κ are the logit-scale intercept and slope for the daily probability γt that an active case recovers at time t(γt=1/(1+e−(κ0+κt))), Z-value was computed at logarithmic scale for positive definite parameters (K,ω,ν,τ), so that a p-value <0.05 indicates significant difference from 1 at 5% level. |
a. First wave
The initial sensitive population estimate is about 100% of the study population size (see Table 5). Each infected transmits the disease to about one individual at the beginning of the disease, indicating a moderate transmission rate, while the reduction factor "a" is weak. Opinion amplification occurs in only 7% of interaction cases (ϕ = 0.07). When there is no control measure, the estimated average number of secondary infections is highly greater than one (R0−2=5.35), and depends more on the reproduction number of prophylactic classes. Regarding the basic reproduction number, it is about 5.35 for the whole model and is more dependent on the reproduction number of the less susceptible population.
(a) First wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.95 | 0.87 | 0.15 | 0 | 3.74 | 1.07 |
Estimate | 4.19 | 1.1 | 0.38 | 0.07 | 3.98 | 1.3 |
UB | 4.42 | 1.33 | 0.62 | 0.31 | 4.21 | 1.53 |
(b) Second wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.67 | 1.22 | 0 | 0 | 2.72 | 0.82 |
Esimate | 3.95 | 1.49 | 0.13 | 0.01 | 2.99 | 1.1 |
UB | 4.23 | 1.78 | 0.41 | 0.29 | 3.28 | 1.38 |
Figure C2a shows the evolution trend of each state of the SIQR-opinion model. Given that the susceptibles with prophylactic levels (-1;-2) are a minority in the population, their dynamics are low. When it has the dynamics of the infected, it is symmetric and reaches a peak of about 50% of the population. The effective reproduction number was less than one from April 2020 and depended more on the number of reproductions in the least susceptible classes.
b. Second wave
About 94% of the target population is represented by the initial population estimate (Table 5). Each infected person will transmit the disease to about two other persons at the beginning of the disease while the reduction factor "a" is too weak. When two opinions of the same nature arise, the chance of an amplification, ϕ, is estimated to be 1%. Note that the initial proportion of the most prophylactic individuals decreased from the first to the second wave, and the probability of opinion amplification was very low. R0 values for different susceptible classes indicate that classes (-2 and -1) need less attention to control disease expansion, while classes (1 and 2) require the highest level of prophylactic measures to control the disease (Table 6). The SIQR-opinion model's evolution trend for each state is shown in Figure C3a. A peak of around 60% (higher than those of the first wave) of the population is reached by the asymmetric dynamics of the infected. The time-varying effective reproduction number has fallen since the period's inception (C3b).
R0−2 | R0−1 | R01 | R02 | R0 | |
Wave1 | 0.50 | 0.39 | 1.43 | 3.03 | 1.36 |
Wave2 | 0.88 | 0.8 | 2.60 | 5.78 | 1.7 |
If there is no adherence to prophylactic behaviors, there is no opinion on the prophylactic levels to consider. When there is no opinion, the epidemic lasts longer (Rt decreases from 4.5 to 1 in about 23 days (Figure C3a2)); however, the peak is lower compared to when there is a prophylactic opinion (Imax=0.48 at t=14 days) (Figure C2a-C3a). Thus, the prophylactic opinion, amplifies the size of the epidemic but better controls its spread. The duration of the epidemic is greater when the population's prophylactic opinion intervenes (Figure 8). The progression of the susceptible (S), infected (I), quarantined (Q), and removed (R) in a population where an individual's opinion does not influence another (C3b1) indicates that the peak infection rate is 49% of initial susceptibles at t = 14 days. The influence increases the maximum number of infected but decreases the duration of the pandemic. The reproduction number has decreased from 2.5 to 1 (Figure C3b2).
We simulated five cases to show the effect of the initial proportion of adherence to prophylactic measures on the dynamics of the pandemic (Table 6). In the case where we considered that 70% of the initial susceptible population is more prophylactic, the peak of new infections is 55% of initial susceptibles at t=12 days. The initial effective reproduction number is 1.8, but the measures are only effective after 36 days. This indicates that the measures taken to reduce transmission are effective but take some time to have an impact. In the case where 98% medium prophylactic is considered (z2=z3=0.49), the peak of newly infected individuals is 0.60 of initial susceptibles at t=11 days. The initial Rt, which is 3.5, becomes less than one about 34 days after the beginning of the pandemic. This indicates that the disease is spreading rapidly despite the prophylactic measures. When 49% of the initial susceptibles population is on one side of the opinion spectrum, the peak of new infections is 0.48 on day 10, and the reproduction number starts around three before decreasing to 1 after 34 days. This suggests that an individual behavior plays an important role in the spread of disease, with some individuals being more susceptible to infection than others.
The initial proportion affects the maximum number of infected that could be obtained, and the most plausible scenario for a minimal number of infected is to have more prophylactics than non-prophylactics. The number of new cases decreases as the proportion of more prophylactics increases until it reaches a given threshold. However, we notice that as the proportion of the most susceptible increases, the time to reach the peak increases.
In Figure 7, we compared the distributions of susceptible, infected, and quarantined individuals and their recoveries when ϕ is low (0.10) and when ϕ is high (0.40) in a predominantly prophylactic population. The ϕ increases the size of the predominantly opinion (S2), especially regarding the most positive one; however, it does not affect the number effective reproduction number. Since it increases the size of the less susceptible, the maximum size of the newly infected when ϕ is high is greater than the peak time for the newly infected when ϕ is low. In the second case, we compared the distributions of susceptibles, infected, quarantines, and recoveries when ϕ is low (0.10) and when ϕ is high (0.40), in a non-prophylactic predominantly population (Figure 7). An increase in the probability of opinion amplification leads to an increase in the susceptible S−2 but in a small proportion compared to most prophylactic cases. The majority opinion outweighs the minority.
Since as the size of the less susceptible increases, the epidemic's size decreases, it is natural that an amplification of the more prophylactic side would reduce the size of the infection. The maximum number of infected decreases when ϕ increases (more than in the absence of the influence of one individual on another)(Figure 8). When ϕ increases, the duration of the epidemic increases as the level of prophylaxis is high in the susceptible population (Figure 8).
As the initial proportion of the most prophylactic class increases, the influence functions reduce the size of the pandemic compared to the case without the influence function, and the linear function reduces the final size of the pandemic at best (Figure 8a). The saturating function decreases the wave's final size less when the susceptible population is less prophylactic (Figure 8b). Fixed and reversed influence functions increase the duration of the epidemic's wave more quickly in a population with a high prophylaxis level. In a population with a low prophylaxis level, the outcome is the same for all influence functions (Figure 8).
We noticed from Figure 9 that the basic reproduction number is below 1 when the reduction parameter a is two, and the pandemic can be controlled (Rt<1).
Opinions and compliance with prophylactic measures have a significant impact on epidemic dynamics [34]. Modeling their effects on the dynamics of an epidemic is crucial for effective decision-making. In this study, we developed a mathematical model to assess the effect of individual behavior towards prophylactic measures on the dynamics of the COVID-19 pandemic in West Africa. For this purpose, we used COVID-19 data from the first case detected in West Africa until the day before the introduction of vaccination. This period corresponds to the first two COVID-19 waves in the region. To avoid identifiability problems when dealing with a large number of parameters [21], we have adjusted the daily infection case data to Richard's growth curve. The unknown parameters were estimated using the maximum likelihood technique. Overall, the Richard model fits the new daily number of confirmed cases well. Despite the lack of fit in the logistic regression, it fits the observed active cases well. The parameters estimated from the Richard and logistic curves are then used to determine the opinion parameters in the SIQR computational model to have more precision due to the lack of fit in phenomenological model estimation [84]. This is a two-step estimation process since the new infections were fitting by minimizing the deviation from the real data while taking the estimated parameters of the growth curve as a basis. Consequently, these estimates of new infections depend on the degree of bias in Richard's model estimates.
To assess the effect of prophylactic behaviors on the disease, we compute the opinion parameter, the basic and effective reproduction numbers. There is a discrepancy between the basic reproduction numbers of the two waves obtained. Our results show the effect of opinions and prophylactic behavior on the dynamics of the disease through the increase in the infection rate from the first to the second wave, which is accompanied by a decrease in the probability of opinion amplification and a decrease in the weight of more prophylactic individuals. These results are consistent with the study of Tyson et al. [34], which showed the importance of opinions in the process of reducing an epidemic. The increase in the infection rate would be the basis of the largest peak observed in the second wave. The decrease in weight and proportion of less susceptible individuals were noticed after the first wave, where West Africans lost confidence in the severity of COVID-19 on the continent and relaxed their prophylactic behavior (Coccia et al. [85]). This relaxation resulted in a larger peak of infection in the second wave.
Our simulations demonstrated that the opinions of susceptible individuals have an impact on the epidemic spread (the R0 and Rt of a population without opinions are higher than those of a population with opinions) [86]. It is worth noting that our simulation was carried out at the beginning of the pandemic when the transmission rate was already high. There are many research works on the spread of SARS-CoV-2, but few have taken into account the opinion of individuals, even though it seems to determine the course of the spread at the beginning of a pandemic. Although the opinion model seems simple, many factors are still difficult to handle (e.g., the correlation between geographical location, gender, age group, and opinion evolution) [87]. Our opinion dynamics model assumes that persuasion is the process by which opinions are changed but that persuasion is also sensitive to information about infection risk. This can also capture the results of knowledge amplification after it circulates on social media. Whatever the relationship between the media and public opinion, it might be more nuanced than we thought.
The results obtained from our simulations suggest that opinion dynamics can have a profound effect on the progression of disease in a population [88,89], and they illustrate the importance of the proportion of opinions at the onset of the epidemic, as well as the relative dynamic speeds of opinions and disease [86]. We simulated several scenarios to highlight the effects of three characteristics of opinion dynamics: influence functions, the initial distribution of opinions along a spectrum, and the degree of opinion amplification. In some simulated scenarios, opinion dynamics significantly reduce the fraction of the population that will be infected and the size of the epidemic's peak. In other scenarios, it is the reverse. We deduce that the intensity of the initial proportion of the less susceptible reduces the propagation dynamics. The most plausible scenario would be to have an equal proportion of all opinions, or more than 50 percent on the more prophylactic sides of the opinion spectrum [68]. Our findings indicate that the initial proportion of susceptible opinions toward disease outbreaks has a major influence on how an epidemic expands, but the effectiveness of those responses doesn't depend solely on them [29]. These simulations also show that the opinion types can interact with each other and the disease dynamics and affect the final size of the epidemic [90]. This result is also consistent with the conclusion of [31] that infectious disease dynamics are often influenced by social and behavioral factors that may interact with each other and with disease dynamics. Different types of influence functions can have varying effects on the spread of pandemics. For example, some types of influence functions will lead to more rapid population responses to the initial increase in infections [92]. In particular, "fixed-order saturating" influence functions may lead to a rapid response. On the other hand, if the initial dominant behavior is not prophylactic, some influence functions, such as linear or reversed order, will lead to the greatest reduction in the final pandemic size [91]. In other words, different influence functions can significantly impact the final outcome of an epidemic. Our results are, therefore, consistent with previous work, highlighting the interaction between opinion and disease dynamics. However, this complexity presents significant challenges for dynamic capture and prediction of epidemics, and our model may under- or overestimate the size of the epidemic peak. As pointed out by Comomdari [93], communication strategies to encourage prophylactic behaviors must take into account social and cultural factors to be effective. Also, adherence to a prophylactic opinion does not imply strict compliance with prophylactic behavior. The proof is that even with 66% adherence at the beginning of the first wave, the transmission was greater than 1. Our work sheds light on how opinion dynamics and influence functions relate to disease dynamics and informs the future development of reliable media and communication functions.
By first fitting curves to observed data (confirmed positive cases, recoveries), this study suggests a hybrid modeling framework combining three approaches: opinions, compartmental, and phenomenological models to assess the effects of prophylactic behaviors on an epidemic dynamic. This model then provides an overall view of the epidemic dynamics by integrating the fitted curves into an opinion dynamics-compartmental model. The proposed method enables estimation of the basic and time-varying reproduction numbers, as well as the peak size of new infections and final epidemic size, and the ability to quickly change the opinion parameter. Application to COVID-19 data from West Africa suggested that its dynamic is heavily influenced by public opinion and behavior. Moreover, contrary to popular belief, the initial proportion of those considering COVID-19 as a severe threat to human health and that of the followers of the prophylactic behavior are decisive in controlling COVID-19 dynamics. The initial proportion of prophylactics in the population, as well as the force of propagation and information sharing, can determine the issue of an epidemic. As a result, it is essential for West African governments to implement control strategies that emphasize public awareness through the media and sensitization.
This work is carried out under the Humboldt Research Hub SEMCA, funded by the German Federal Foreign Office with the support of the Alexander von Humboldt Foundation (AvH).
The authors declare there is no conflict of interest.
Population size C(t) | Population rate ˙C(t) | Population acceleration ¨C(t) |
K(1+e−ut)−1/ν | Kωe−ut(1+e−ut)−ν+1ν | νωe−ut(ν+1νe−ut1+e−ut−1)˙C(t) |
Table notes: ut=[1+ωνρ(t−τ)]−1/ρ; Source: Tovissode et al. [20]. |
Countries | Date of the first implementation of prophylactic measures |
Burkina Faso | 27 April 2020 |
Ivory Coast | 23 March 2020 |
Ghana | 13 March 2020 |
Guinea | 27 March 2020 |
Nigeria | 27 April 2020 |
Senegal | March 2020 |
Benin | 8 April 2020 |
Mauritania | 14 May 2020 |
Source: https://hsfnotes.com/africa/2020/05/22/covid-19-initial-responses-of-certain-african-countries/#page=1 |
Countries | Cumulative cases | Deaths | Population | Recoveries |
Benin | 5643 | 70 | 12996895 | 561362 |
Burkina Faso | 11868 | 141 | 22100683 | 839192 |
Ivory Cost | 32158 | 188 | 27478249 | 4629735 |
Cabo Verde | 15089 | 144 | 587925 | 1768788 |
Ghana | 80759 | 582 | 32833031 | 11298593 |
Guinea | 15487 | 87 | 13531906 | 2617480 |
Gambia | 4712 | 146 | 2639916 | 569375 |
Guinea-Bissau | 3156 | 47 | 2060721 | 421487 |
Liberia | 1999 | 85 | 5193416 | 298618 |
Mali | 8324 | 348 | 21904983 | 830340 |
Mauritania | 17130 | 437 | 4614974 | 2037288 |
Niger | 4744 | 172 | 25252722 | 445668 |
Nigeria | 153187 | 1875 | 213401323 | 14227914 |
Senegal | 33242 | 832 | 16876720 | 3445409 |
Sierra Leone | 3862 | 79 | 8420641 | 448026 |
Togo | 6466 | 81 | 8644829 | 518870 |
West_Africa | 397826 | 5314 | 4.19E+08 | 44958145 |
[1] |
Drachman DA (2005) Do we have brain to spare? Neurology 64: 2004-2005. doi: 10.1212/01.WNL.0000166914.38327.BB
![]() |
[2] |
Beul SF, Hilgetag CC (2019) Neuron density fundamentally relates to architecture and connectivity of the primate cerebral cortex. Neuroimage 189: 777-792. doi: 10.1016/j.neuroimage.2019.01.010
![]() |
[3] | Cunningham EL, McGuinness B, Herron B, et al. (2015) Dementia. Ulster Med J 84: 79-87. |
[4] | Alzheimer's Disease International (2014) Dementia in the Asia Pacific Region. Alzheimer's Disease International Report, London Available from: https://www.alzint.org/resource/dementia-in-the-asia-pacific-region/. |
[5] | Europe A (2019) Dementia in Europe yearbook 2019: Estimating the prevalence of dementia in Europe Luxembourg: Alzheimer Europe, 1-102. |
[6] | Alzheimer's disease facts and figures (2020) Alzheimer's Dement. Alzheimer's Association Report 2020 Available from: https://doi.org/10.1002/alz.12068. |
[7] | Kumar CTS, Shaji KS, Varghese M, et al. (2019) Dementia in India 2020 Cochin: Alzheimer's and Related Disorders Society of India (ARDSI), 1-96. |
[8] |
Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828. doi: 10.1016/S1474-4422(11)70072-2
![]() |
[9] | Fleming R, Zeisel J, Bennett K (2020) World Alzheimer Report 2020: Design Dignity Dementia: dementia-related design and the built environment Volume 1: Case Studies London, England: Alzheimer's Disease International, 1-248. |
[10] |
Trevisan K, Cristina-Pereira R, Silva-Amaral D, et al. (2019) Theories of Aging and the Prevalence of Alzheimer's Disease. Biomed Res Int 2019: 1-9. doi: 10.1155/2019/9171424
![]() |
[11] | Alzheimer A (1987) About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L Jarvik and H Greenson). Alzheimer Dis Assoc Disord 1: 3-8. |
[12] |
Tiraboschi P, Hansen LA, Thal LJ, et al. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62: 1984-1989. doi: 10.1212/01.WNL.0000129697.01779.0A
![]() |
[13] |
Carter J, Lippa CF (2001) Beta-Amyloid, Neuronal Death and Alzheimers Disease. Curr Mol Med 1: 733-737. doi: 10.2174/1566524013363177
![]() |
[14] |
Medina M, Hernández F, Avila J (2016) New features about tau function and dysfunction. Biomolecules 6: 21. doi: 10.3390/biom6020021
![]() |
[15] |
Castellani RJ, Perry G (2019) Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges. J Alzheimers Dis 67: 447-467. doi: 10.3233/JAD-180721
![]() |
[16] |
Zvěřová M (2019) Clinical aspects of Alzheimer's disease. Clin Biochem 72: 3-6. doi: 10.1016/j.clinbiochem.2019.04.015
![]() |
[17] |
Yang Y, Kandiah N, Kim S, et al. (2020) Clinical aspects of neurobehavioral symptoms of dementia. Dement Neurocogn Disord 19: 54-64. doi: 10.12779/dnd.2020.19.2.54
![]() |
[18] |
Raz L, Knoefel J, Bhaskar K (2016) The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 36: 172-186. doi: 10.1038/jcbfm.2015.164
![]() |
[19] |
Livingston G, Huntley J, Sommerlad A, et al. (2020) Dementia prevention, intervention, and care: report of the Lancet Commission. Lancet 396: 413-446. doi: 10.1016/S0140-6736(20)30367-6
![]() |
[20] |
Kelly AM (2018) Exercise-induced modulation of neuroinflammation in models of Alzheimer's disease. Brain Plast 4: 81-94. doi: 10.3233/BPL-180074
![]() |
[21] |
Saha P, Sen N (2019) Tauopathy: A common mechanism for neurodegeneration and brain aging. Mech Ageing Dev 178: 72-79. doi: 10.1016/j.mad.2019.01.007
![]() |
[22] |
Hernandez F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64: 2219-2233. doi: 10.1007/s00018-007-7220-x
![]() |
[23] |
Šimić G, Babić Leko M, Wray S, et al. (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6: 6. doi: 10.3390/biom6010006
![]() |
[24] |
Vickers JC, Dickson TC, Adlard PA, et al. (2000) The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol 60: 139-165. doi: 10.1016/S0301-0082(99)00023-4
![]() |
[25] |
Serrano-Pozo A, Frosch MP, Masliah E, et al. (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1: a006189. doi: 10.1101/cshperspect.a006189
![]() |
[26] | Wenk GL (2003) Neuropathologic Changes in Alzheimer's Disease. J Clin Psychiatry 64: 7-10. |
[27] |
Priller C, Bauer T, Mitteregger G, et al. (2006) Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 26: 7212-7221. doi: 10.1523/JNEUROSCI.1450-06.2006
![]() |
[28] |
Turner PR, O'connor K, Tate WP, et al. (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1-32. doi: 10.1016/S0301-0082(03)00089-3
![]() |
[29] |
Sastre M, Steiner H, Fuchs K, et al. (2001) Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835-841. doi: 10.1093/embo-reports/kve180
![]() |
[30] |
Selkoe DJ (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110: 1375-1381. doi: 10.1172/JCI0216783
![]() |
[31] | Dingledine R, Borges K, Bowie D, et al. (1999) The glutamate receptor ion channels. Pharmacol Rev 51: 7-62. |
[32] |
Hu M, Liu QS, Chang KT, et al. (2002) Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. Mol Cell Neurosci 21: 616-625. doi: 10.1006/mcne.2002.1202
![]() |
[33] |
Yakel JL (2013) Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflügers Archi 465: 441-450. doi: 10.1007/s00424-012-1200-1
![]() |
[34] |
Hussain I, Powell D, Howlett DR, et al. (1999) Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci 14: 419-427. doi: 10.1006/mcne.1999.0811
![]() |
[35] |
Seubert P, Oltersdorf T, Lee MG, et al. (1993) Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature 361: 260-263. doi: 10.1038/361260a0
![]() |
[36] |
Hashimoto M, Rockenstein E, Crews L, et al. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4: 21-36. doi: 10.1385/NMM:4:1-2:21
![]() |
[37] |
Peng C, Trojanowski JQ, Lee VM (2020) Protein transmission in neurodegenerative disease. Nat Rev Neurol 16: 199-212. doi: 10.1038/s41582-020-0333-7
![]() |
[38] |
Mattson MP, Guo ZH, Geiger JD (1999) Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J Neurochem 73: 532-537. doi: 10.1046/j.1471-4159.1999.0730532.x
![]() |
[39] |
Snyder EM, Nong Y, Almeida CG, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8: 1051-1058. doi: 10.1038/nn1503
![]() |
[40] |
Gu Z, Liu W, Yan Z (2009) β-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem 284: 10639-10649. doi: 10.1074/jbc.M806508200
![]() |
[41] |
Tozaki H, Matsumoto A, Kanno T, et al. (2002) The inhibitory and facilitatory actions of amyloid-β peptides on nicotinic ACh receptors and AMPA receptors. Biochem Biophys Rese Communn 294: 42-45. doi: 10.1016/S0006-291X(02)00429-1
![]() |
[42] |
Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24: 149-156. doi: 10.1016/j.ijdevneu.2005.11.010
![]() |
[43] |
Bojarski L, Herms J, Kuznicki J (2008) Calcium dysregulation in Alzheimer's disease. Neurochem Int 52: 621-633. doi: 10.1016/j.neuint.2007.10.002
![]() |
[44] |
Van der Kant R, Goldstein LS, Ossenkoppele R (2020) Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci 21: 21-35. doi: 10.1038/s41583-019-0240-3
![]() |
[45] | Ramesh G, MacLean AG, Philipp MT (2013) Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013: 480739. |
[46] |
Alberghina L, Colangelo AM (2006) The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. BMC Neurosci 7: S2. doi: 10.1186/1471-2202-7-S1-S2
![]() |
[47] |
Gunn AP, Wong BX, Johanssen T, et al. (2016) Amyloid-β peptide Aβ3pE-42 induces lipid peroxidation, membrane permeabilization, and calcium influx in neurons. J Biol Chem 291: 6134-6145. doi: 10.1074/jbc.M115.655183
![]() |
[48] |
Gan X, Huang S, Wu L, et al. (2014) Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim Biophys Acta 1842: 220-231. doi: 10.1016/j.bbadis.2013.11.009
![]() |
[49] |
Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-1439. doi: 10.1111/j.1471-4159.2007.05194.x
![]() |
[50] |
Town T, Zolton J, Shaffner R, et al. (2002) p35/Cdk5 pathway mediates soluble amyloid-β peptide-induced tau phosphorylation in vitro. J Neurosci Res 69: 362-372. doi: 10.1002/jnr.10299
![]() |
[51] |
Das A, Dikshit M, Nath C (2005) Role of molecular isoforms of acetylcholinesterase in learning and memory functions. Pharmacol Biochem Behav 81: 89-99. doi: 10.1016/j.pbb.2005.02.006
![]() |
[52] |
Tiwari P, Dwivedi S, Singh MP, et al. (2013) Basic and modern concepts on cholinergic receptor: A review. Asian Pac J Trop Dis 3: 413-420. doi: 10.1016/S2222-1808(13)60094-8
![]() |
[53] | Leonard BE (2004) Pharmacotherapy in the treatment of Alzheimer's disease: an update. World Psychiatry 3: 84-88. |
[54] |
Gutteridge JM, Halliwell B (2000) Free radicals and antioxidants in the year 2000: a historical look to the future. Ann N Y Acad Sci 899: 136-147. doi: 10.1111/j.1749-6632.2000.tb06182.x
![]() |
[55] |
Uttara B, Singh AV, Zamboni P, et al. (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7: 65-74. doi: 10.2174/157015909787602823
![]() |
[56] |
Mancuso C, Scapagini G, Curro D, et al. (2007) Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 12: 1107-1123. doi: 10.2741/2130
![]() |
[57] |
Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366: 211-223. doi: 10.1016/S0005-2728(98)00114-5
![]() |
[58] |
Fernie AR, Carrari F, Sweetlove LJ (2004) Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol 7: 254-261. doi: 10.1016/j.pbi.2004.03.007
![]() |
[59] |
Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344. doi: 10.1113/jphysiol.2003.049478
![]() |
[60] |
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623. doi: 10.1111/j.1471-4159.1992.tb10990.x
![]() |
[61] |
Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14: 45-53. doi: 10.1016/j.molmed.2007.12.002
![]() |
[62] |
Reddy PH, Tripathi R, Troung Q, et al. (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822: 639-649. doi: 10.1016/j.bbadis.2011.10.011
![]() |
[63] |
Reddy PH, McWeeney S, Park BS, et al. (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13: 1225-1240. doi: 10.1093/hmg/ddh140
![]() |
[64] |
Tran M, Reddy PH (2021) Defective Autophagy and Mitophagy in Aging and Alzheimer's Disease. Front Neurosci 14: 612757. doi: 10.3389/fnins.2020.612757
![]() |
[65] |
Pradeepkiran JA, Reddy PH (2020) Defective mitophagy in Alzheimer's disease. Ageing Res Rev 64: 101191. doi: 10.1016/j.arr.2020.101191
![]() |
[66] |
Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415: 136-148. doi: 10.1016/j.brainres.2011.07.052
![]() |
[67] |
Garbarino VR, Orr ME, Rodriguez KA, et al. (2015) Mechanisms of oxidative stress resistance in the brain: lessons learned from hypoxia tolerant extremophilic vertebrates. Arch Biochem Biophys 576: 8-16. doi: 10.1016/j.abb.2015.01.029
![]() |
[68] |
Gerlach M, Ben-Shachar D, Riederer P, et al. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807. doi: 10.1046/j.1471-4159.1994.63030793.x
![]() |
[69] |
Chance B, Sies H, Boveris A (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527-605. doi: 10.1152/physrev.1979.59.3.527
![]() |
[70] |
Hirai K, Aliev G, Nunomura A, et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023. doi: 10.1523/JNEUROSCI.21-09-03017.2001
![]() |
[71] |
Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37: 289-305. doi: 10.1016/j.biocel.2004.07.009
![]() |
[72] |
Chao CC, Hu S, Sheng WS, et al. (1996) Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16: 276-284. doi: 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X
![]() |
[73] |
Biber K, Vinet J, Boddeke HW (2008) Neuron-microglia signaling: chemokines as versatile messengers. J Neuroimmunol 198: 69-74. doi: 10.1016/j.jneuroim.2008.04.012
![]() |
[74] |
Perkins ND (2007) Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 8: 49-62. doi: 10.1038/nrm2083
![]() |
[75] |
O'Neill LA, Kaltschmidt C (1997) NF-kB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20: 252-258. doi: 10.1016/S0166-2236(96)01035-1
![]() |
[76] |
Friedlander RM (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375. doi: 10.1056/NEJMra022366
![]() |
[77] |
Katsimpardi L, Lledo PM (2018) Regulation of neurogenesis in the adult and aging brain. Curr Opin Neurobiol 53: 131-138. doi: 10.1016/j.conb.2018.07.006
![]() |
[78] | Anjum I, Fayyaz M, Wajid A, et al. (2018) Does obesity increase the risk of dementia: a literature review. Cureus 10: e2660. |
[79] |
Verdile G, Keane KN, Cruzat VF, et al. (2015) Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediators Inflamm 2015: 105828. doi: 10.1155/2015/105828
![]() |
[80] |
Nameni G, Farhangi MA, Hajiluian G, et al. (2017) Insulin deficiency: a possible link between obesity and cognitive function. Int J Dev Neurosci 59: 15-20. doi: 10.1016/j.ijdevneu.2017.02.008
![]() |
[81] |
Steen E, Terry BM, Rivera EJ, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? J Alzheimers Dis 7: 63-80. doi: 10.3233/JAD-2005-7107
![]() |
[82] |
Craft S (2005) Insulin resistance syndrome and Alzheimer's disease: age-and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26: 65-69. doi: 10.1016/j.neurobiolaging.2005.08.021
![]() |
[83] |
Dye L, Boyle NB, Champ C, et al. (2017) The relationship between obesity and cognitive health and decline. Proc Nutr Soc 76: 443-454. doi: 10.1017/S0029665117002014
![]() |
[84] |
Skoog I, Gustafson D (2003) Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res 25: 675-680. doi: 10.1179/016164103101201986
![]() |
[85] |
Luchsinger JA, Reitz C, Patel B, et al. (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64: 570-575. doi: 10.1001/archneur.64.4.570
![]() |
[86] |
Luchsinger JA, Tang MX, Shea S, et al. (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63: 1187-1192. doi: 10.1212/01.WNL.0000140292.04932.87
![]() |
[87] |
Tiehuis AM, Van der Graaf Y, Visseren FL, et al. (2008) Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 39: 1600-1603. doi: 10.1161/STROKEAHA.107.506089
![]() |
[88] |
Li ZG, Zhang W, Sima AA (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56: 1817-1824. doi: 10.2337/db07-0171
![]() |
[89] |
Ho L, Qin W, Pompl PN, et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904. doi: 10.1096/fj.03-0978fje
![]() |
[90] |
Bennett RG, Hamel FG, Duckworth WC (2003) An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52: 2315-2320. doi: 10.2337/diabetes.52.9.2315
![]() |
[91] |
Shiiki T, Ohtsuki S, Kurihara A, et al. (2004) Brain insulin impairs amyloid-β (1–40) clearance from the brain. J Neurosci 24: 9632-9637. doi: 10.1523/JNEUROSCI.2236-04.2004
![]() |
[92] |
Lee HJ, Seo HI, Cha HY, et al. (2018) Diabetes and Alzheimer's disease: mechanisms and nutritional aspects. Clin Nutr Res 7: 229-240. doi: 10.7762/cnr.2018.7.4.229
![]() |
[93] |
Xi YD, Li XY, Ding J, et al. (2013) Soy isoflavone alleviates Aβ1-42-induced impairment of learning and memory ability through the regulation of RAGE/LRP-1 in neuronal and vascular tissue. Curr Neurovasc Res 10: 144-156. doi: 10.2174/1567202611310020007
![]() |
[94] |
Deane R, Wu Z, Sagare A, et al. (2004) LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43: 333-344. doi: 10.1016/j.neuron.2004.07.017
![]() |
[95] |
Lloret A, Monllor P, Esteve D, et al. (2019) Obesity as a risk factor for Alzheimer's disease: implication of leptin and glutamate. Front Neurosci 13: 508. doi: 10.3389/fnins.2019.00508
![]() |
[96] |
Bird TD (2008) Genetic aspects of Alzheimer disease. Genet Med 10: 231-239. doi: 10.1097/GIM.0b013e31816b64dc
![]() |
[97] |
Kang J, Lemaire HG, Unterbeck A, et al. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736. doi: 10.1038/325733a0
![]() |
[98] |
Weidemann A, König G, Bunke D, et al. (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57: 115-126. doi: 10.1016/0092-8674(89)90177-3
![]() |
[99] |
Scheuner D, Eckman C, Jensen M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870. doi: 10.1038/nm0896-864
![]() |
[100] |
Sherrington R, Rogaev EI, Liang Y, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760. doi: 10.1038/375754a0
![]() |
[101] |
Theuns J, Del-Favero J, Dermaut B, et al. (2000) Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. Hum Mol Genet 9: 325-331. doi: 10.1093/hmg/9.3.325
![]() |
[102] |
Citron M, Westaway D, Xia W, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72. doi: 10.1038/nm0197-67
![]() |
[103] |
Moehlmann T, Winkler E, Xia X, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 99: 8025-8030. doi: 10.1073/pnas.112686799
![]() |
[104] |
Levy-Lahad E, Wasco W, Poorkaj P, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977. doi: 10.1126/science.7638622
![]() |
[105] |
Sherrington R, Froelich S, Sorbi S, et al. (1996) Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5: 985-988. doi: 10.1093/hmg/5.7.985
![]() |
[106] |
Kovacs DM, Fausett HJ, Page KJ, et al. (1996) Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 2: 224-229. doi: 10.1038/nm0296-224
![]() |
[107] |
Corder EH, Saunders AM, Strittmatter WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923. doi: 10.1126/science.8346443
![]() |
[108] |
Nicoll JA, Roberts GW, Graham DI (1995) Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1: 135-137. doi: 10.1038/nm0295-135
![]() |
[109] |
Liu Y, Laakso MP, Karonen JO, et al. (2002) Apolipoprotein E polymorphism and acute ischemic stroke: a diffusion- and perfusion-weighted magnetic resonance imaging study. J Cereb Blood Flow Metab 22: 1336-1342. doi: 10.1097/01.WCB.0000033200.58646.B3
![]() |
[110] | Horsburgh K, McCulloch J, Nilsen M, et al. (2000) Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci 12: 4309-4317. |
[111] | Huang Y (2006) Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr Opin Drug Discov Devel 9: 627-641. |
[112] |
Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103: 5644-5651. doi: 10.1073/pnas.0600549103
![]() |
[113] |
Nagy Z, Esiri MM, Jobst KA, et al. (1995) Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neurosci 69: 757-761. doi: 10.1016/0306-4522(95)00331-C
![]() |
[114] |
Gibson GE, Haroutunian V, Zhang H, et al. (2000) Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 48: 297-303. doi: 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z
![]() |
[115] |
Yamanaka A, Sakurai T, Katsumoto T, et al. (1999) Chronic intracerebroventricular administration of orexin—A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849: 248-252. doi: 10.1016/S0006-8993(99)01905-8
![]() |
[116] |
Chow M, Cao M (2016) The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nat Sci Sleep 8: 81-86. doi: 10.2147/NSS.S114969
![]() |
[117] |
Tsuneki H, Wada T, Sasaoka T (2012) Role of orexin in the central regulation of glucose and energy homeostasis. Endocr J 59: 365-374. doi: 10.1507/endocrj.EJ12-0030
![]() |
[118] |
Ben J, Soares FM, Cechetti F, et al. (2009) Exercise effects on activities of Na+, K+-ATPase, acetylcholinesterase and adenine nucleotides hydrolysis in ovariectomized rats. Brain Res 1302: 248-255. doi: 10.1016/j.brainres.2009.09.013
![]() |
[119] |
Feng P, Vurbic D, Wu Z, et al. (2008) Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J Psychopharmacol 22: 784-791. doi: 10.1177/0269881106082899
![]() |
[120] |
Liguori C, Romigi A, Nuccetelli M, et al. (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71: 1498-1505. doi: 10.1001/jamaneurol.2014.2510
![]() |
[121] |
Osorio RS, Ducca EL, Wohlleber ME, et al. (2016) Orexin—A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects. Sleep 39: 1253-1260. doi: 10.5665/sleep.5846
![]() |
[122] |
Slats D, AHR Claassen J, Jan Lammers G, et al. (2012) Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res 9: 1119-1125. doi: 10.2174/156720512804142840
![]() |
[123] | Davies J, Chen J, Pink R, et al. (2015) Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. Sci Rep 5: 1-2. |
[124] |
Jaussent I, Bouyer J, Ancelin ML, et al. (2012) Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep 35: 1201-1207. doi: 10.5665/sleep.2070
![]() |
[125] |
Suh SW, Han JW, Lee JR, et al. (2018) Sleep and cognitive decline: a prospective nondemented elderly cohort study. Ann Neurol 83: 472-482. doi: 10.1002/ana.25166
![]() |
[126] | American Academy of Sleep Medicine (2014) International Classification of Sleep Disorders Illinois: Darien, 1-383. |
[127] |
Sadeghmousavi S, Eskian M, Rahmani F, et al. (2020) The effect of insomnia on development of Alzheimer's disease. J Neuroinflammation 17: 289. doi: 10.1186/s12974-020-01960-9
![]() |
[128] |
Gehrman PR, Martin JL, Shochat T, et al. (2003) Sleep-disordered breathing and agitation in institutionalized adults with Alzheimer disease. Am J Geriatr Psychiatry 11: 426-433. doi: 10.1097/00019442-200307000-00005
![]() |
[129] |
Andrade AG, Bubu OM, Varga AW, et al. (2018) The Relationship between Obstructive Sleep Apnea and Alzheimer's Disease. J Alzheimers Dis 64: S255-S270. doi: 10.3233/JAD-179936
![]() |
[130] |
Pan W, Kastin AJ (2014) Can sleep apnea cause Alzheimer's disease? Neurosci Biobehav Rev 47: 656-669. doi: 10.1016/j.neubiorev.2014.10.019
![]() |
[131] | Weldemichael DA, Grossberg GT (2010) Circadian rhythm disturbances in patients with Alzheimer's disease: a review. Int J Alzheimers Dis 2010: 716453. |
[132] |
Bhidayasiri R, Sringean J, Rattanachaisit W, et al. (2017) The sleeping brain in Parkinson's disease: A focus on REM sleep behaviour disorder and related parasomnias for practicing neurologists. J Neurol Sci 374: 32-37. doi: 10.1016/j.jns.2017.01.018
![]() |
[133] |
Panel CC, Watson NF, Badr MS, Belenky G, et al. (2015) Joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society on the recommended amount of sleep for a healthy adult: methodology and discussion. Sleep 38: 1161-1183. doi: 10.5665/sleep.4886
![]() |
[134] |
Matricciani L, Bin YS, Lallukka T, et al. (2017) Past, present, and future: trends in sleep duration and implications for public health. Sleep Health 3: 317-323. doi: 10.1016/j.sleh.2017.07.006
![]() |
[135] |
Lo JC, Groeger JA, Cheng GH, et al. (2016) Self-reported sleep duration and cognitive performance in older adults: a systematic review and meta-analysis. Sleep Med 17: 87-98. doi: 10.1016/j.sleep.2015.08.021
![]() |
[136] |
Peter-Derex L, Yammine P, Bastuji H, et al. (2015) Sleep and Alzheimer's disease. Sleep Med Rev 19: 29-38. doi: 10.1016/j.smrv.2014.03.007
![]() |
[137] |
Camargos EF, Louzada FM, Nóbrega OT (2013) Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness, and challenges. Sleep Med Rev 17: 475-488. doi: 10.1016/j.smrv.2013.01.006
![]() |
[138] |
Brzecka A, Leszek J, Ashraf GM, et al. (2018) Sleep disorders associated with Alzheimer's disease: a perspective. Front Neurosci 12: 330. doi: 10.3389/fnins.2018.00330
![]() |
[139] | Tsolaki A, Kazis D, Kompatsiaris I, et al. (2014) Electroencephalogram and Alzheimer's disease: clinical and research approaches. Int J Alzheimers Dis 2014: 349249. |
[140] |
Wu YH, Feenstra MG, Zhou JN, et al. (2003) Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 88: 5898-5906. doi: 10.1210/jc.2003-030833
![]() |
[141] |
Fossati S, Cam J, Meyerson J, et al. (2010) Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-β variants in cells composing the cerebral vessel walls. FASEB J 24: 229-241. doi: 10.1096/fj.09-139584
![]() |
[142] |
Washington PM, Morffy N, Parsadanian M, et al. (2014) Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-beta in an Alzheimer's disease mouse model. J Neurotrauma 31: 125-134. doi: 10.1089/neu.2013.3017
![]() |
[143] |
Washington PM, Villapol S, Burns MP (2016) Polypathology and dementia after brain trauma: does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy? Exp Neurol 275: 381-388. doi: 10.1016/j.expneurol.2015.06.015
![]() |
[144] |
Ramos-Cejudo J, Wisniewski T, Marmar C, et al. (2018) Traumatic brain injury and Alzheimer's disease: the cerebrovascular link. EBioMedicine 28: 21-30. doi: 10.1016/j.ebiom.2018.01.021
![]() |
[145] |
Elahi FM, Miller BL (2017) A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 13: 457-476. doi: 10.1038/nrneurol.2017.96
![]() |
[146] |
Lim X, Yeo JM, Green A, et al. (2013) The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies: a systematic review and meta-analysis. Parkinsonism Relat d 19: 851-858. doi: 10.1016/j.parkreldis.2013.06.008
![]() |
[147] |
Watson R, Colloby SJ, Blamire AM, et al. (2015) Assessment of regional gray matter loss in dementia with Lewy bodies: a surface-based MRI analysis. Am J Geriatr Psychiatry 23: 38-46. doi: 10.1016/j.jagp.2014.07.005
![]() |
[148] |
Chow N, Aarsland D, Honarpisheh H, et al. (2012) Comparing hippocampal atrophy in Alzheimer's dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 34: 44-50. doi: 10.1159/000339727
![]() |
[149] |
Lebedev AV, Westman E, Beyer MK, et al. (2013) Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol 260: 1104-1115. doi: 10.1007/s00415-012-6768-z
![]() |
[150] |
Watson R, O'Brien JT, Barber R, et al. (2012) Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study. Int Psychogeriatr 24: 532-540. doi: 10.1017/S1041610211002171
![]() |
[151] |
Whitwell JL, Weigand SD, Shiung MM, et al. (2007) Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 130: 708-719. doi: 10.1093/brain/awl388
![]() |
[152] |
Watson R, Blamire AM, Colloby SJ, et al. (2012) Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 79: 906-914. doi: 10.1212/WNL.0b013e318266fc51
![]() |
[153] |
Galvin JE, Price JL, Yan Z, et al. (2011) Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 76: 1797-1803. doi: 10.1212/WNL.0b013e31821ccc83
![]() |
[154] |
Johnson KA, Fox NC, Sperling RA, et al. (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006213. doi: 10.1101/cshperspect.a006213
![]() |
[155] |
McKeith I, O'Brien J, Walker Z, et al. (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6: 305-313. doi: 10.1016/S1474-4422(07)70057-1
![]() |
[156] |
Brigo F, Turri G, Tinazzi M (2015) 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci 359: 161-171. doi: 10.1016/j.jns.2015.11.004
![]() |
[157] |
Shimizu S, Hanyu H, Kanetaka H, et al. (2005) Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dement Geriatr Cogn Disord 20: 25-30. doi: 10.1159/000085070
![]() |
[158] |
Hanyu H, Shimizu S, Hirao K, et al. (2006) Comparative value of brain perfusion SPECT and [(123) I] MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 33: 248-253. doi: 10.1007/s00259-005-1921-x
![]() |
[159] |
Yoshita M, Arai H, Arai H, et al. (2015) Diagnostic accuracy of 123 I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PloS One 10: e0120540. doi: 10.1371/journal.pone.0120540
![]() |
[160] |
Edison P, Rowe CC, Rinne JO, et al. (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338. doi: 10.1136/jnnp.2007.127878
![]() |
[161] |
Kantarci K, Lowe VJ, Boeve BF, et al. (2017) AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 81: 58-67. doi: 10.1002/ana.24825
![]() |
[162] |
Coleman KK, Coleman BL, MacKinley JD, et al. (2016) Detection and differentiation of frontotemporal dementia and related disorders from alzheimer disease using the Montreal Cognitive Assessment. Alzheimer Dis Assoc Disord 30: 258-263. doi: 10.1097/WAD.0000000000000119
![]() |
[163] |
Kuhlmann J, Andreasson U, Pannee J, et al. (2017) CSF Aβ1–42—an excellent but complicated Alzheimer's biomarker—a route to standardisation. Clinica Chimica Acta 467: 27-33. doi: 10.1016/j.cca.2016.05.014
![]() |
[164] |
Lashley T, Schott JM, Weston P, et al. (2018) Molecular biomarkers of Alzheimer's disease: progress and prospects. Dis Models Mech 11: dmm031781. doi: 10.1242/dmm.031781
![]() |
[165] |
Morbelli S, Bauckneht M (2018) Amyloid PET imaging: standardization and integration with other Alzheimer's disease biomarkers. In Biomarkers for Alzheimer's Disease Drug Development New York, NY: Humana Press, 203-212. doi: 10.1007/978-1-4939-7704-8_13
![]() |
[166] |
Olsson B, Lautner R, Andreasson U, et al. (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15: 673-684. doi: 10.1016/S1474-4422(16)00070-3
![]() |
[167] |
Guzman-Martinez L, Maccioni RB, Farías GA, et al. (2019) Biomarkers for Alzheimer's Disease. Curr Alzheimer Res 16: 518-528. doi: 10.2174/1567205016666190517121140
![]() |
[168] |
Gill SS, Rochon PA, Herrmann N, et al. (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330: 445. doi: 10.1136/bmj.38330.470486.8F
![]() |
[169] |
Giacobini E, Pepeu G (2006) Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. Brain Cholinergic Syst Health Dis 235-264. doi: 10.1201/b14486-19
![]() |
[170] |
Li WM, Pi RB, Chan HH, et al. (2005) Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J Biol Chem 280: 18179-18188. doi: 10.1074/jbc.M411085200
![]() |
[171] |
Hyde C, Peters J, Bond M, et al. (2013) Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing 42: 14-20. doi: 10.1093/ageing/afs165
![]() |
[172] |
Lipton SA (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2: 155-165. doi: 10.2174/1567205053585846
![]() |
[173] |
Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45: 583-595. doi: 10.1016/j.neuint.2004.03.007
![]() |
[174] |
Liperoti R, Pedone C, Corsonello A (2008) Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 6: 117-124. doi: 10.2174/157015908784533860
![]() |
[175] |
Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms. Pharmacol Ther 125: 169-179. doi: 10.1016/j.pharmthera.2009.10.010
![]() |
[176] |
Vigen CL, Mack WJ, Keefe RS, et al. (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 168: 831-839. doi: 10.1176/appi.ajp.2011.08121844
![]() |
[177] |
Ralph SJ, Espinet AJ (2018) Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep 2: 1-26. doi: 10.3233/ADR-170042
![]() |
[178] |
Doody RS, Raman R, Farlow M, et al. (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369: 341-350. doi: 10.1056/NEJMoa1210951
![]() |
[179] |
Coric V, Salloway S, van Dyck CH, et al. (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA neurology 72: 1324-1333. doi: 10.1001/jamaneurol.2015.0607
![]() |
[180] |
Muntimadugu E, Dhommati R, Jain A, et al. (2016) Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci 92: 224-234. doi: 10.1016/j.ejps.2016.05.012
![]() |
[181] |
Das B, Yan R (2019) A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. CNS Drugs 33: 251-263. doi: 10.1007/s40263-019-00613-7
![]() |
[182] |
Egan MF, Kost J, Voss T, et al. (2019) Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med 380: 1408-1420. doi: 10.1056/NEJMoa1812840
![]() |
[183] |
Burki T (2018) Alzheimer's disease research: the future of BACE inhibitors. Lancet 391: 2486. doi: 10.1016/S0140-6736(18)31425-9
![]() |
[184] |
Henley D, Raghavan N, Sperling R, et al. (2019) Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med 380: 1483-1485. doi: 10.1056/NEJMc1813435
![]() |
[185] |
Wong KH, Riaz MK, Xie Y, et al. (2019) Review of current strategies for delivering Alzheimer's disease drugs across the blood-brain barrier. Int J Mol Sci 20: 381. doi: 10.3390/ijms20020381
![]() |
[186] |
Di Benedetto G, Burgaletto C, Carta AR, et al. (2019) Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. J Neuroinflammation 16: 166. doi: 10.1186/s12974-019-1554-9
![]() |
[187] |
Quitterer U, AbdAlla SN (2020) Improvements of symptoms of Alzheimers disease by inhibition of the angiotensin system. Pharmacol Res 154: 104230. doi: 10.1016/j.phrs.2019.04.014
![]() |
[188] |
Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106: 13594-13599. doi: 10.1073/pnas.0901402106
![]() |
[189] |
Blurton-Jones M, Spencer B, Michael S, et al. (2014) Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther 5: 46. doi: 10.1186/scrt440
![]() |
[190] |
Ager RR, Davis JL, Agazaryan A, et al. (2015) Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. Hippocampus 25: 813-826. doi: 10.1002/hipo.22405
![]() |
[191] |
Martini AC, Forner S, Trujillo-Estrada L, et al. (2018) Past to future: what animal models have taught us about Alzheimer's disease. J Alzheimers Dis 64: S365-S378. doi: 10.3233/JAD-179917
![]() |
[192] |
Briggs R, Kennelly SP, O'Neill D (2016) Drug treatments in Alzheimer's disease. Clin Med 16: 247-253. doi: 10.7861/clinmedicine.16-3-247
![]() |
[193] | Cummings J, Lee G, Ritter A, et al. (2020) Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement TRCI 6: e12050. |
[194] | Bennett T, Bray D, Neville MW (2014) Suvorexant, a dual orexin receptor antagonist for the management of insomnia. Pharm Ther 39: 264-266. |
[195] |
Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R (2017) Understanding sleep-wake mechanisms and drug discovery. Expert Opin Drug Discov 12: 643-657. doi: 10.1080/17460441.2017.1329818
![]() |
[196] | Steiner MA, Winrow CJ (2014) Insomnia and beyond-Exploring the therapeutic potential of orexin receptor antagonists. Frontiers Research Topics E-book series Switzerland: Frontiers Media SA, 1-219. |
[197] |
Pradeepkiran JA, Reddy PH (2019) Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer's disease. Cells 8: 260. doi: 10.3390/cells8030260
![]() |
[198] | Rêgo ML, Cabral DA, Costa EC, et al. (2019) Physical exercise for individuals with hypertension: It is time to emphasize its benefits on the brain and cognition. Clin Med Insights Cardiol 13: 1179546819839411. |
[199] |
Archer T, Josefsson T, Lindwall M (2014) Effects of physical exercise on depressive symptoms and biomarkers in depression. CNS Neurol Disord Drug Targets 13: 1640-1653. doi: 10.2174/1871527313666141130203245
![]() |
[200] |
Vina J, Sanchis-Gomar F, Martinez-Bello V, et al. (2012) Exercise acts as a drug; the pharmacological benefits of exercise. Br J Pharmacol 167: 1-12. doi: 10.1111/j.1476-5381.2012.01970.x
![]() |
[201] |
Daré LR, Garcia A, Neves BH, et al. (2020) One Physical Exercise Session Promotes Recognition Learning In Rats With Cognitive Deficits Related To Amyloid Beta Neurotoxicity. Brain Res 1744: 146918. doi: 10.1016/j.brainres.2020.146918
![]() |
[202] |
Carro E, Trejo JL, Busiguina S, et al. (2001) Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci 21: 5678-5684. doi: 10.1523/JNEUROSCI.21-15-05678.2001
![]() |
[203] |
He XF, Liu DX, Zhang Q, et al. (2017) Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. Front Mol Neurosci 10: 144. doi: 10.3389/fnmol.2017.00144
![]() |
[204] | Baker LD, Frank LL, Foster-Schubert K, et al. (2010) Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 67: 71-79. |
[205] |
Lange-Asschenfeldt C, Kojda G (2008) Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise: from vessels to neurons. Exp Gerontol 43: 499-504. doi: 10.1016/j.exger.2008.04.002
![]() |
[206] | Ziemann E, Zembroñ-Lacny A, Kasperska A, et al. (2013) Exercise training-induced changes in inflammatory mediators and heat shock proteins in young tennis players. J Sports Sci Med 12: 282-289. |
[207] |
Bobinski F, Teixeira JM, Sluka KA, et al. (2018) IL-4 mediates the analgesia produced by low-intensity exercise in mice with neuropathic pain. Pain 159: 437-450. doi: 10.1097/j.pain.0000000000001109
![]() |
[208] |
Liu Y, Chu JM, Yan T, et al. (2020) Short-term resistance exercise inhibits neuroinflammation and attenuates neuropathological changes in 3xTg Alzheimer's disease mice. J Neuroinflammation 17: 4. doi: 10.1186/s12974-019-1653-7
![]() |
[209] |
Saucedo Marquez CM, Vanaudenaerde B, Troosters T, et al. (2015) High-intensity interval training evokes larger serum BDNF levels compared with intense continuous exercise. J Appl Physiol 119: 1363-1373. doi: 10.1152/japplphysiol.00126.2015
![]() |
[210] |
Pajonk FG, Wobrock T, Gruber O, et al. (2010) Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiat 67: 133-143. doi: 10.1001/archgenpsychiatry.2009.193
![]() |
[211] |
Adlard PA, Perreau VM, Pop V, et al. (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25: 4217-4221. doi: 10.1523/JNEUROSCI.0496-05.2005
![]() |
[212] |
Um HS, Kang EB, Koo JH, et al. (2011) Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer's disease. Neurosci Res 69: 161-173. doi: 10.1016/j.neures.2010.10.004
![]() |
[213] |
Leem YH, Lim HJ, Shim SB, et al. (2009) Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies. J Neurosci Res 87: 2561-2570. doi: 10.1002/jnr.22075
![]() |
[214] |
Belarbi K, Burnouf S, Fernandez-Gomez FJ, et al. (2011) Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis 43: 486-494. doi: 10.1016/j.nbd.2011.04.022
![]() |
[215] |
Alkadhi KA, Dao AT (2018) Exercise decreases BACE and APP levels in the hippocampus of a rat model of Alzheimer's disease. Mol Cell Neurosci 86: 25-29. doi: 10.1016/j.mcn.2017.11.008
![]() |
[216] |
Hashiguchi D, Campos HC, Wuo-Silva R, et al. (2020) Resistance Exercise Decreases Amyloid Load and Modulates Inflammatory Responses in the APP/PS1 Mouse Model for Alzheimer's Disease. J Alzheimers Dis 73: 1525-1539. doi: 10.3233/JAD-190729
![]() |
[217] |
Mankhong S, Kim S, Moon S, et al. (2020) Effects of Aerobic Exercise on Tau and Related Proteins in Rats with the Middle Cerebral Artery Occlusion. Int J Mol Sci 21: 5842. doi: 10.3390/ijms21165842
![]() |
[218] | Khazaeinia T, Ramsey AA, Tam YK (2020) The effects of exercise on the pharmacokinetics of drugs. J Pharm Pharm Sci 3: 292-302. |
[219] |
Taylor D (2014) Physical activity is medicine for older adults. Postgrad Med J 90: 26-32. doi: 10.1136/postgradmedj-2012-131366
![]() |
[220] | World Health Organization WHO guidelines on physical activity and sedentary behaviour: at a glance (2020) .Available from: World Health Organization. https://apps.who.int/iris/handle/10665/337001. Licence: CC BY-NC-SA 3.0 IGO, 1–17. |
[221] | Spirduso WW, Francis K, MacRae P (1995) Physical dimensions of aging USA Champaign Illinois: Human kinetics, 1-432. |
[222] |
Van Praag H, Shubert T, Zhao C, et al. (2005) Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 25: 8680-8685. doi: 10.1523/JNEUROSCI.1731-05.2005
![]() |
[223] |
Lledo PM, Alonso M, Grubb MS (2006) Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci 7: 179-193. doi: 10.1038/nrn1867
![]() |
[224] |
Erickson KI, Voss MW, Prakash RS, et al. (2011) Exercise training increases size of hippocampus and improves memory. PNAS 108: 3017-3022. doi: 10.1073/pnas.1015950108
![]() |
[225] |
Erickson KI, Kramer AF (2009) Aerobic exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med 43: 22-24. doi: 10.1136/bjsm.2008.052498
![]() |
[226] | Voss MW, Prakash RS, Erickson KI, et al. (2010) Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Front Aging Neurosci 2: 32. |
[227] |
Langlois F, Vu TT, Chassé K, et al. (2013) Benefits of physical exercise training on cognition and quality of life in frail older adults. J Gerontol:Series B 68: 400-404. doi: 10.1093/geronb/gbs069
![]() |
[228] | Geda YE, Roberts RO, Knopman DS, et al. (2010) Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol 67: 80-86. |
[229] |
Nuzum H, Stickel A, Corona M, et al. (2020) Potential benefits of physical activity in MCI and dementia. Behav Neurol 2020: 7807856. doi: 10.1155/2020/7807856
![]() |
[230] |
Burns JM, Cronk BB, Anderson HS, et al. (2008) Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology 71: 210-216. doi: 10.1212/01.wnl.0000317094.86209.cb
![]() |
[231] |
Chen WW, Zhang X, Huang WJ (2016) Role of physical exercise in Alzheimer's disease. Biomed Rep 4: 403-407. doi: 10.3892/br.2016.607
![]() |
[232] |
Teri L, Gibbons LE, McCurry SM, et al. (2003) Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 290: 2015-2022. doi: 10.1001/jama.290.15.2015
![]() |
[233] | Teri L, McCurry SM, Buchner DM, et al. (1998) Exercise and activity level in Alzheimer's disease: a potential treatment focus. J Rehabil Res Dev 35: 411-419. |
[234] |
Palleschi L, Vetta F, De Gennaro E, et al. (1996) Effect of aerobic training on the cognitive performance of elderly patients with senile dementia of Alzheimer type. Arch Gerontol Geriatr 22: 47-50. doi: 10.1016/0167-4943(96)86912-3
![]() |
[235] |
George EK, Reddy PH (2019) Can healthy diets, regular exercise, and better lifestyle delay the progression of dementia in elderly individuals? J Alzheimers Dis 72: S37-S58. doi: 10.3233/JAD-190232
![]() |
[236] | Fitzgerald PB, Daskalakis ZJ (2013) Repetitive transcranial magnetic stimulation treatment for depressive disorders: a practical guide. Springer Science & Business Media, Germany: Springer-Verlag Berlin Heidelberg, 1-121. |
[237] |
Weiler M, Stieger KC, Long JM, et al. (2020) Transcranial Magnetic Stimulation in Alzheimer's disease: are we ready? eNeuro 7. doi: 10.1523/ENEURO.0235-19.2019
![]() |
[238] | Abraham G, Milev R, Lazowski L, et al. (2007) Repetitive transcranial magnetic stimulation for treatment of elderly patients with depression—an open label trial. Neuropsychiatr Dis Treat 3: 919-924. |
[239] |
Cotelli M, Manenti R, Cappa SF, et al. (2008) Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. Eur J Neurol 15: 1286-1292. doi: 10.1111/j.1468-1331.2008.02202.x
![]() |
[240] |
Cotelli M, Calabria M, Manenti R, et al. (2011) Improved language performance in Alzheimer disease following brain stimulation. J Neurol Neurosurg Psychiatry 82: 794-797. doi: 10.1136/jnnp.2009.197848
![]() |
[241] |
Rutherford G, Lithgow B, Moussavi Z (2015) Short and long-term effects of rTMS treatment on Alzheimer's disease at different stages: a pilot study. J Exp Neurosci 9: 43-51. doi: 10.4137/JEN.S24004
![]() |
[242] |
Koch G, Bonnì S, Pellicciari MC, et al. (2018) Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. Neuroimage 169: 302-311. doi: 10.1016/j.neuroimage.2017.12.048
![]() |
[243] |
Rabey JM, Dobronevsky E (2016) Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: clinical experience. J Neural Transm 123: 1449-1455. doi: 10.1007/s00702-016-1606-6
![]() |
[244] |
Yang YW, Pan WX, Xie Q (2020) Combined effect of repetitive transcranial magnetic stimulation and physical exercise on cortical plasticity. Neural Regen Res 15: 1986-1994. doi: 10.4103/1673-5374.282239
![]() |
[245] |
Ross RE, VanDerwerker CJ, Newton JH, et al. (2018) Simultaneous aerobic exercise and rTMS: Feasibility of combining therapeutic modalities to treat depression. Brain Stimul 11: 245-246. doi: 10.1016/j.brs.2017.10.019
![]() |
[246] |
Reed T, Kadosh RC (2018) Transcranial electrical stimulation (tES) mechanisms and its effects on cortical excitability and connectivity. J Inherit Metab Dis 41: 1123-1130. doi: 10.1007/s10545-018-0181-4
![]() |
[247] |
Zarifkar AH, Zarifkar A, Nami M, et al. (2018) The Comparison of the Effects of Different Transcranial Electrical Stimulation (tES) Paradigms on Beta-Amyloid (Aβ 25–35)-Induced Memory Impairment upon Morris Water Maze Task in Male Rats. J Neurol Neurosci 9: 265. doi: 10.21767/2171-6625.1000265
![]() |
[248] |
Steinberg F, Pixa NH, Fregni F (2019) A review of acute aerobic exercise and transcranial direct current stimulation effects on cognitive functions and their potential synergies. Front Hum Neurosci 12: 534. doi: 10.3389/fnhum.2018.00534
![]() |
1. | Leah LeJeune, Navid Ghaffarzadegan, Lauren M. Childs, Omar Saucedo, Mathematical analysis of simple behavioral epidemic models, 2024, 375, 00255564, 109250, 10.1016/j.mbs.2024.109250 |
ωi(I) | Linear | Saturating | Fixed-order saturating | Reverse-order saturating |
ω−2(I) | ω0(1+ωmaxI) | ω0(1+ωmaxI2k2+I2) | ω0(1+ωmaxIk+I) | ω0(1+12ωmaxIk+I) |
ω−1(I) | ω0(1+12ωmaxI) | ω0(1+12ωmaxIk+I) | ω0(1+12ωmaxIk+I) | ω0(1+ωmaxIk+I) |
ω1(I) | ω0(1−12I) | ω0(12+12I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) | ω0(I−1k−1+I−1) |
ω2(I) | ω0(1−I) | ω0(I−2k−2+I−2) | ω0(I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) |
Source: Tyson et al. [34]. Ecological functional responses give the lead-up to the linear and saturating influence functions. A modification to the saturating function, called the fixed-order saturating function, prevents the influence functions' ordering from changing for low levels of infection. When some preventive behaviors are judged as socially unacceptable, and an inversion of the influence ordering is possible, the reverse-order saturating influence function is used. |
Parameter | Description | Values | Unit | Source |
a | Factor discounting of the infection rate | estimated | ||
α | Removal rate of non detected infectives | 1/10 | - | Assumed |
ϕ | Baseline probability of opinion amplification | estimated | - | |
w0 | Baseline influence rate (when disease is not perceived) | 0.1 | percentage−1 | Tyson et al. [34] |
w∞ | Skewness parameter of influence functions | estimated | - | |
k | Half-influence saturation constant | estimated | day−1 | |
δ | Rate of detecting new cases of infected people | 0.009 | Honfo et al. [79] | |
β0 | Baseline transmission rate by I infectious | estimated | day−1 | |
βi | Transmission rate by infectious with opinion i | estimated | day−1 | |
γ | Removal rate of quarantined people | estimated | ||
K | carrying capacity or maximum cumulative case incidence | estimated | ind. | |
ν | growth acceleration parameter | estimated | ||
ω | the growth rate constant | estimated | day−1 | |
τ | constant of integration determined by the | estimated | ||
initial conditions of the epidemic. | day−1 |
Wave | Selection criterion | Richards-Poisson | Richards-Nbinomial | Richards-Lognorm |
Wave1 | AIC | 17177.84 | 3105.51 | 3149.41 |
R2(Y) | 0.83 | 0.79 | 0.79 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Wave2 | AIC | 13268.57 | 1798.62 | 1794.54 |
R2(Y) | 0.82 | 0.82 | 0.82 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Tablenote: Akaike Information Criterion AIC; New infected detected Y; cumul as cumulative |
(a) First wave | ||||||
Parameter | Estimate | Std.Error | z | P (>— z —) | CI | |
K | 206746 | 495.5 | 417.154 | < 0.001 | 205800 | 207700 |
ω | 0.093 | 0.002 | 46.500 | < 0.001 | 0.089 | 0.099 |
ν | 0.266 | 0.008 | 33.250 | < 0.001 | 0.2505 | 0.282 |
τ | 72.730 | 1.625 | 44.757 | < 0.001 | 69.550 | 75.920 |
κ0 | -4.612 | 0.026 | -177.21 | < 0.001 | -4.663 | -4.561 |
κ1 | 0.016 | 0.0003 | 45.390 | < 0.001 | 0.015 | 0.017 |
κ2 | -4.2E-05 | 1.125E-06 | -37.45 | < 0.001 | -4.434E-05 | -3.993E-05 |
(b) Second wave | ||||||
Estimate | Std.Error | z | P (>— z —) | CI | ||
K | 238299 | 771.3 | 308.959 | < 0.001 | 236800 | 239800 |
ω | 0.027 | 0.0002 | 135 | < 0.001 | 0.027 | 0.027 |
ν | 3.05 | 0.066 | 46.212 | < 0.001 | 2.923 | 3.183 |
τ | 350.4 | 0.207 | 1692.754 | < 0.001 | 350 | 350.8 |
κ0 | -1.913 | 0.227 | -8.416 | < 0.001 | -2.358 | -1.467 |
κ1 | -0.007 | 0.002 | -4.917 | < 0.001 | -0.010 | -0.004 |
κ2 | 1.26E-05 | 2.404E-06 | 5.238 | < 0.001 | 7.878E-06 | 1.730E-05 |
Table notes: ind. is individuals, K>0 is the ultimate pandemic size (detected) or maximum cumulative case incidence, ν>0 is a growth acceleration parameter, ω>0( day −1) is the "intrinsic" growth rate constant and τ is a constant of integration determined by the initial conditions of the epidemic, κ0 and κ are the logit-scale intercept and slope for the daily probability γt that an active case recovers at time t(γt=1/(1+e−(κ0+κt))), Z-value was computed at logarithmic scale for positive definite parameters (K,ω,ν,τ), so that a p-value <0.05 indicates significant difference from 1 at 5% level. |
(a) First wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.95 | 0.87 | 0.15 | 0 | 3.74 | 1.07 |
Estimate | 4.19 | 1.1 | 0.38 | 0.07 | 3.98 | 1.3 |
UB | 4.42 | 1.33 | 0.62 | 0.31 | 4.21 | 1.53 |
(b) Second wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.67 | 1.22 | 0 | 0 | 2.72 | 0.82 |
Esimate | 3.95 | 1.49 | 0.13 | 0.01 | 2.99 | 1.1 |
UB | 4.23 | 1.78 | 0.41 | 0.29 | 3.28 | 1.38 |
R0−2 | R0−1 | R01 | R02 | R0 | |
Wave1 | 0.50 | 0.39 | 1.43 | 3.03 | 1.36 |
Wave2 | 0.88 | 0.8 | 2.60 | 5.78 | 1.7 |
Population size C(t) | Population rate ˙C(t) | Population acceleration ¨C(t) |
K(1+e−ut)−1/ν | Kωe−ut(1+e−ut)−ν+1ν | νωe−ut(ν+1νe−ut1+e−ut−1)˙C(t) |
Table notes: ut=[1+ωνρ(t−τ)]−1/ρ; Source: Tovissode et al. [20]. |
Countries | Date of the first implementation of prophylactic measures |
Burkina Faso | 27 April 2020 |
Ivory Coast | 23 March 2020 |
Ghana | 13 March 2020 |
Guinea | 27 March 2020 |
Nigeria | 27 April 2020 |
Senegal | March 2020 |
Benin | 8 April 2020 |
Mauritania | 14 May 2020 |
Source: https://hsfnotes.com/africa/2020/05/22/covid-19-initial-responses-of-certain-african-countries/#page=1 |
Countries | Cumulative cases | Deaths | Population | Recoveries |
Benin | 5643 | 70 | 12996895 | 561362 |
Burkina Faso | 11868 | 141 | 22100683 | 839192 |
Ivory Cost | 32158 | 188 | 27478249 | 4629735 |
Cabo Verde | 15089 | 144 | 587925 | 1768788 |
Ghana | 80759 | 582 | 32833031 | 11298593 |
Guinea | 15487 | 87 | 13531906 | 2617480 |
Gambia | 4712 | 146 | 2639916 | 569375 |
Guinea-Bissau | 3156 | 47 | 2060721 | 421487 |
Liberia | 1999 | 85 | 5193416 | 298618 |
Mali | 8324 | 348 | 21904983 | 830340 |
Mauritania | 17130 | 437 | 4614974 | 2037288 |
Niger | 4744 | 172 | 25252722 | 445668 |
Nigeria | 153187 | 1875 | 213401323 | 14227914 |
Senegal | 33242 | 832 | 16876720 | 3445409 |
Sierra Leone | 3862 | 79 | 8420641 | 448026 |
Togo | 6466 | 81 | 8644829 | 518870 |
West_Africa | 397826 | 5314 | 4.19E+08 | 44958145 |
ωi(I) | Linear | Saturating | Fixed-order saturating | Reverse-order saturating |
ω−2(I) | ω0(1+ωmaxI) | ω0(1+ωmaxI2k2+I2) | ω0(1+ωmaxIk+I) | ω0(1+12ωmaxIk+I) |
ω−1(I) | ω0(1+12ωmaxI) | ω0(1+12ωmaxIk+I) | ω0(1+12ωmaxIk+I) | ω0(1+ωmaxIk+I) |
ω1(I) | ω0(1−12I) | ω0(12+12I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) | ω0(I−1k−1+I−1) |
ω2(I) | ω0(1−I) | ω0(I−2k−2+I−2) | ω0(I−1k−1+I−1) | ω0(12+12I−1k−1+I−1) |
Source: Tyson et al. [34]. Ecological functional responses give the lead-up to the linear and saturating influence functions. A modification to the saturating function, called the fixed-order saturating function, prevents the influence functions' ordering from changing for low levels of infection. When some preventive behaviors are judged as socially unacceptable, and an inversion of the influence ordering is possible, the reverse-order saturating influence function is used. |
Parameter | Description | Values | Unit | Source |
a | Factor discounting of the infection rate | estimated | ||
α | Removal rate of non detected infectives | 1/10 | - | Assumed |
ϕ | Baseline probability of opinion amplification | estimated | - | |
w0 | Baseline influence rate (when disease is not perceived) | 0.1 | percentage−1 | Tyson et al. [34] |
w∞ | Skewness parameter of influence functions | estimated | - | |
k | Half-influence saturation constant | estimated | day−1 | |
δ | Rate of detecting new cases of infected people | 0.009 | Honfo et al. [79] | |
β0 | Baseline transmission rate by I infectious | estimated | day−1 | |
βi | Transmission rate by infectious with opinion i | estimated | day−1 | |
γ | Removal rate of quarantined people | estimated | ||
K | carrying capacity or maximum cumulative case incidence | estimated | ind. | |
ν | growth acceleration parameter | estimated | ||
ω | the growth rate constant | estimated | day−1 | |
τ | constant of integration determined by the | estimated | ||
initial conditions of the epidemic. | day−1 |
Wave | Selection criterion | Richards-Poisson | Richards-Nbinomial | Richards-Lognorm |
Wave1 | AIC | 17177.84 | 3105.51 | 3149.41 |
R2(Y) | 0.83 | 0.79 | 0.79 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Wave2 | AIC | 13268.57 | 1798.62 | 1794.54 |
R2(Y) | 0.82 | 0.82 | 0.82 | |
R2(cumul(Y)) | 0.99 | 0.99 | 0.99 | |
Tablenote: Akaike Information Criterion AIC; New infected detected Y; cumul as cumulative |
(a) First wave | ||||||
Parameter | Estimate | Std.Error | z | P (>— z —) | CI | |
K | 206746 | 495.5 | 417.154 | < 0.001 | 205800 | 207700 |
ω | 0.093 | 0.002 | 46.500 | < 0.001 | 0.089 | 0.099 |
ν | 0.266 | 0.008 | 33.250 | < 0.001 | 0.2505 | 0.282 |
τ | 72.730 | 1.625 | 44.757 | < 0.001 | 69.550 | 75.920 |
κ0 | -4.612 | 0.026 | -177.21 | < 0.001 | -4.663 | -4.561 |
κ1 | 0.016 | 0.0003 | 45.390 | < 0.001 | 0.015 | 0.017 |
κ2 | -4.2E-05 | 1.125E-06 | -37.45 | < 0.001 | -4.434E-05 | -3.993E-05 |
(b) Second wave | ||||||
Estimate | Std.Error | z | P (>— z —) | CI | ||
K | 238299 | 771.3 | 308.959 | < 0.001 | 236800 | 239800 |
ω | 0.027 | 0.0002 | 135 | < 0.001 | 0.027 | 0.027 |
ν | 3.05 | 0.066 | 46.212 | < 0.001 | 2.923 | 3.183 |
τ | 350.4 | 0.207 | 1692.754 | < 0.001 | 350 | 350.8 |
κ0 | -1.913 | 0.227 | -8.416 | < 0.001 | -2.358 | -1.467 |
κ1 | -0.007 | 0.002 | -4.917 | < 0.001 | -0.010 | -0.004 |
κ2 | 1.26E-05 | 2.404E-06 | 5.238 | < 0.001 | 7.878E-06 | 1.730E-05 |
Table notes: ind. is individuals, K>0 is the ultimate pandemic size (detected) or maximum cumulative case incidence, ν>0 is a growth acceleration parameter, ω>0( day −1) is the "intrinsic" growth rate constant and τ is a constant of integration determined by the initial conditions of the epidemic, κ0 and κ are the logit-scale intercept and slope for the daily probability γt that an active case recovers at time t(γt=1/(1+e−(κ0+κt))), Z-value was computed at logarithmic scale for positive definite parameters (K,ω,ν,τ), so that a p-value <0.05 indicates significant difference from 1 at 5% level. |
(a) First wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.95 | 0.87 | 0.15 | 0 | 3.74 | 1.07 |
Estimate | 4.19 | 1.1 | 0.38 | 0.07 | 3.98 | 1.3 |
UB | 4.42 | 1.33 | 0.62 | 0.31 | 4.21 | 1.53 |
(b) Second wave. | ||||||
S0 | β0 | k | ϕ | ωmax | a | |
LB | 3.67 | 1.22 | 0 | 0 | 2.72 | 0.82 |
Esimate | 3.95 | 1.49 | 0.13 | 0.01 | 2.99 | 1.1 |
UB | 4.23 | 1.78 | 0.41 | 0.29 | 3.28 | 1.38 |
R0−2 | R0−1 | R01 | R02 | R0 | |
Wave1 | 0.50 | 0.39 | 1.43 | 3.03 | 1.36 |
Wave2 | 0.88 | 0.8 | 2.60 | 5.78 | 1.7 |
Population size C(t) | Population rate ˙C(t) | Population acceleration ¨C(t) |
K(1+e−ut)−1/ν | Kωe−ut(1+e−ut)−ν+1ν | νωe−ut(ν+1νe−ut1+e−ut−1)˙C(t) |
Table notes: ut=[1+ωνρ(t−τ)]−1/ρ; Source: Tovissode et al. [20]. |
Countries | Date of the first implementation of prophylactic measures |
Burkina Faso | 27 April 2020 |
Ivory Coast | 23 March 2020 |
Ghana | 13 March 2020 |
Guinea | 27 March 2020 |
Nigeria | 27 April 2020 |
Senegal | March 2020 |
Benin | 8 April 2020 |
Mauritania | 14 May 2020 |
Source: https://hsfnotes.com/africa/2020/05/22/covid-19-initial-responses-of-certain-african-countries/#page=1 |
Countries | Cumulative cases | Deaths | Population | Recoveries |
Benin | 5643 | 70 | 12996895 | 561362 |
Burkina Faso | 11868 | 141 | 22100683 | 839192 |
Ivory Cost | 32158 | 188 | 27478249 | 4629735 |
Cabo Verde | 15089 | 144 | 587925 | 1768788 |
Ghana | 80759 | 582 | 32833031 | 11298593 |
Guinea | 15487 | 87 | 13531906 | 2617480 |
Gambia | 4712 | 146 | 2639916 | 569375 |
Guinea-Bissau | 3156 | 47 | 2060721 | 421487 |
Liberia | 1999 | 85 | 5193416 | 298618 |
Mali | 8324 | 348 | 21904983 | 830340 |
Mauritania | 17130 | 437 | 4614974 | 2037288 |
Niger | 4744 | 172 | 25252722 | 445668 |
Nigeria | 153187 | 1875 | 213401323 | 14227914 |
Senegal | 33242 | 832 | 16876720 | 3445409 |
Sierra Leone | 3862 | 79 | 8420641 | 448026 |
Togo | 6466 | 81 | 8644829 | 518870 |
West_Africa | 397826 | 5314 | 4.19E+08 | 44958145 |